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Abstract
Pharmaceutical drugs are one of the most socially important heath care products.
They are part of many individuals’ everyday lives, from the eradicating of diseases at
birth to treating patients at the end of life. However, for many patients access is
prevented due to expensive cost. This study explored cost-related non-adherence
(CRN) and researched if reimportation of pharmaceutical drugs from other countries
could increase patient drug adherence. The perceptions of 10 patients and 10
providers in Maine were assessed. Maine is the only state that allowed its citizens to
purchase prescription drugs from abroad. The research questions addressed (a) how
reimportation drugs could contribute to drug adherence, (b) the perceptions of
patients, and (c) the perceptions of key providers of reimportation. This study was
guided by a theoretical framework utilizing Kurt Lewin’s theory of organizational
change. Participants answered 15 open-ended questions. The study utilized a
qualitative grounded theory approach; data were analyzed inductively. The research
demonstrated that patients and healthcare providers had positive perceptions for a
reimportation policy. Future research of other regions for this topic should prevail.
Member checking was used to validate the emerging theories of increased long term
drug adherence incentivized by affordable drug cost, which contributes to perception
of competence, better management of current disease, and decreased safety concerns.
Positive social change implications can be achieved through savings to the healthcare industry by creating a pathway to affordable drugs that will bring more drugs to
market and create a competitive structure that can drive down pricing.
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Chapter 1: Introduction to the Study
Introduction
Per capita expenditures for prescribed drugs are much greater in the United States than
other developed nations. The United States’ population for cost related non-adherence (CRN)
are doubled that of Canadian residents (Kennedy & Morgan, 2009). Kanavos, Ferrario,
Vandoros, and Anderson (2013) found that brand drug prices increased from 5% to 198% in the
United States within the past decade. According to a 2013 survey by Health Affairs, drug prices
in the United States are so high that more than 50 million American patients (21%) are currently
skipping doses or never getting the prescription filled (Cohen,Whitney, Kirzinger and Gindi
2013). Patients often skip doses in an attempt to save money; however, this tactic is most likely
to increase personal healthcare costs (Cohen, et al, 2013).
Stuart (2014) suggested that increased pharmaceutical spending is partially due to the
rapid uptake of newer and more expensive drugs in comparison to other nations. For example,
Celebrex (a nonsteroidal anti-inflammatory drug used for the treatment of pain or inflammation)
has an average cost of $225USD in the United States, which is twice as much as the cost in
Britain ($112USD) and four-times as much as the cost in Canada ($51USD). Higher prices for
mandated prescription drugs lead to prescriptions not being filled (Stuart 2014). Therefore, cost
is a contributing factor to patients’ non-adherence (Khatter & Dickens, 2006). In particular,
retired, senior citizens may experience a lapse in Medicare insurance coverage and leave
prescription drug request unfulfilled (Khatter & Dickens, 2006).
The purpose of this research was to analyze the perceptions of Maine citizens with
chronic diseases and recurring prescription drug refills concerning reimportation of
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pharmaceutical drugs. State legislation allowed low-cost drugs to be reimported. The overall
effects of this policy were also analyzed. In this chapter, I discuss the background, problem
statement, research questions, hypotheses, theoretical framework, nature of the study, definitions,
assumptions, scope/delimitations, limitations, and significance of the study. More importantly, I
discuss the implications for positive social change and how savings to the healthcare system and
patients can ensue; while giving increase accessibility to much needed expensive medications.
Social, health, and economic costs of chronic disease management are high and knowledge about
potentially greater and cheaper access to prescription drugs can improve the overall health of the
individual and community.
Background
According to the Alliance for Health Reform (2006) reimportation of prescription drugs
has gained momentum in the political discourse. Having other incentives in place to help
supplement expensive drugs (such as Medicaid Part D) is needed. Thus, other alternatives
measures are required; reimportation of medication drugs could be one of those alternatives.
Views on reimportation are polarized (safe for U.S. citizens or not safe for citizens) amongst
those who support and oppose this measure with both sides attempting to justify their voices
(Bhosle & Balkrishnan 2007). The Medicine Equity and Drug Safety Act of 2000 (MEDS Act)
allowed certain institutions to reimport U.S. manufactured, and Food and Drug Administration
(FDA) approved drugs, exported outside the United States back into the United States at a
discounted price (Bhosle & Balkrishnan 2007). However, because of the lack of approved votes
in Congress by the Department of Health and Human Services (HHS) the MEDS Act was
terminated in December 2000 (Bhosle & Balkrishnan, 2007). The opposing concern for
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reimportation is safety. According to former Secretary of Health and Human Services, Donna
Shalala, prescription drugs that are made in the United States, shipped overseas, can safely be
reimported (CDC.gov, Retrieved 2015). Former Secretary Donna Shalala stated that the FDA
can monitor the safety of drugs coming back into the United States for $24 million more in the
budget in order to increase inspection services (Kaiser Health, 2009).
Ho, Bryson, and Rumsfeld, (2009) stated as a result of high drug prices and the need for
less expensive drugs there is a system within healthcare that contributes to patients
nonadherence to drug medication. There are many studies exploring nonadherence. Many
chronic diseases have been researched for patients’ nonadherence levels (Brown & Bussell,
2011). Medication nonadherence has been a growing concern to healthcare providers and other
stakeholders due to increased evidence that it is linked to adverse reactions and increased longterm healthcare costs (Ho et al, 2009).
Diabetes is a chronic disease that is prevalent throughout the nation and regionally in
Maine. According to the Centers for Disease Control (CDC), (2014) undiagnosed and diagnosed
diabetes in the United States totaled 29.1 million citizens or 9.3% of the population having
diabetes. Diagnosed population consisted of 21.0 million people and undiagnosed consisted of
8.1 million people; also 27.8% of citizens with diabetes are not diagnosed. According to the
official Maine website (Maine.gov),(2014) diabetes is one of four contributing diseases to the
state’s mortality rate. It is imperative to investigate options to decrease mortality rates and
improve quality of life. Affordable medication from other markets would allow for exploration
of patients’ adherence levels. This research gave researchers, healthcare officials and others,
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data (not seen in any other regions of the country) options, and corrective measures needed for
patients’ ability to maintain physician’s guided drug regimen.
Problem Statement
A plethora of research literature exists on patients’ medication non-adherence practices.
There also exists literature on cost determinants of drugs and affordability. But literature gaps are
present in terms of research providing data concerning reimportation of drugs as one corrective
measure to patients’ mandated drug regimen. This is in part because of the current policies and
the federal government denial of reimportation drugs into the United States’ markets. Therefore,
research is needed to understand the impact of reimportation on non-adherence drug regimen.
Accomplishments of this study can be obtained by studying the one state that has legislation in
place. Healthcare officials, politicians and others are then allowed to evaluate the perceptions of
Maine’s population as they are free to reimport medication.
The research study explored the link between patient drug nonadherence and
reimportation of drugs. Utilization of a qualitative approach allowed for the experiences,
opinions, and feelings of the informants to form a hypothesis. Increasing supply and opening the
market to other countries will bring more prescriptions to market. Purchase of prescriptions
drugs at a lower cost from a different market through reimportation will render immediate
savings that may contribute to increased drug adherence.
According to Kennedy, Coyne, Joseph and Sclar (2004) a small but increasing
population of United States’ citizens are unable to purchase medications that are prescribed to
them. Cost-related nonadherence is similar to other health care access issues; it is not evenly
distributed among the population. Senior citizens on fixed incomes often make the decision to
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purchase food or purchase their monthly prescription drugs (Carrns, 2012); as a result, drugs are
not taken or prescriptions are not filled at all. Chronic illnesses continue to get worse, and higher
healthcare treatment cost ensues. The change in locations of drug purchases significantly
decreases the cost. Citizens given the opportunity to save a tremendous amount of money on
prescription drugs could experience enhanced long-term healthcare benefits due to their ability to
purchase and comply. Cleemput and Kesteloot (2002) stated that it is an important factor of
impediment to the effects of health interventions; gaps exist between efficacy and effectiveness
due to non-compliances. Research is needed to explore if reimportation of medication drugs and
the effects of reimportation have an effect on patients’ adherence. It may contribute to decreasing
long-term healthcare cost and improve the disease state of patients.
The purpose of this proposed research was to explore one component of patient nonadherence of prescription drugs (CRA) and investigate if reimportation policies will enhance
drug adherence among the Americans with chronic diseases. The study looked at non-adherence
due to CRA that causes patients to skip dosages or not fill the prescription at all. Newly
implemented policies in the state of Maine have adopted reimportation drug laws for its citizens.
The study assessed the perception of this population in relationship to the newly implemented
reimportation law in the state of Maine.
Purpose of Study
The purpose of the study was to determine the perceptions and explore the influences of
drug reimportation policy on chronic disease patients in the state of Maine. This new legislation
was selected for its uniqueness within the United States. The research attempted to further
demonstrate optional corrective measures for patients’ medication regimen and interpret the
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perceptions of the participants from the data collected. It is the desire of this research to
contribute data on a national scale that could be replicated in other states.
Research Questions
Research questions were formulated to correspond to interview questions in order to
capture patients’ and provider’s perception of this process. The questionnaires/interviews were
designed to address the following research questions:
RQ1: How does a reimportation prescription drug policy contribute to patients’ drug
adherence?
RQ2: What perceptions do patients have about reimportation drugs as related to a chronic
disease?
RQ3: What are the perceptions of key providers (physicians, physician assistants
& nurse practitioners) regarding the impact of reimportation drug laws on patient
medication adherents?
Theoretical Framework
The U.S. government has many layers of political management thereby creating a
complex bureaucratic process. This can lead to frustration from the general population and the
willingness for change is diminished. There is a need for new and better legislation from political
officials and for better internal processes. Kurt Lewin’s (1947) theory of organizational change
proposes a thought process that could be utilized. Kurt Lewin’s previous works consisted of
studies within leadership and various effects of leadership (Burnes, 2004). Morrison (2014)
noted that Lewin focused his attention on group based decision-making, developing the force
field theory, unfreeze, change and refreeze change management models with action research, and
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the group approach to training dynamics. With a focus on three distinct stages of change
management: (a) unfreezing, (b) change (transition), and (c) refreezing he suggested unfreezing
is the method that involves locating a process to make possible for people to relinquish
counterproductive old habits and patterns.
Unfreezing is needed to overcome the levels of resistance and group conformity that
allows for moving to a new stage or changing movement. Secondly, change/transition is needed
to have change in thoughts, feelings, behaviors, or all three that results in liberation, and increase
productivity. Lastly, refreezing is putting into place the newly accepted changes into a new
accepted habit; it now becomes standard operating procedure (Morrison, 2014). It is possible to
revert to the old habits without this implementation. Adaptation and implementation of new
policies is built upon this framework. Organizations, leaders, and others must acknowledge a
new mindset which is imperative to employ new national legislation related to prescription
drugs. Many processes and strategies could increase the chance of health policies and programs
to be adopted and enforced within formal institutions (Kritsonis, 2005).
Nature of Study
I explored the perception of individuals residing in Maine in order to determine if the
reimportation policies have any effect(s) on patients’ perceptions of medication adherence. In
my research I used semi-structured questionnaires/interviews to produce data on a sample
participant pool diagnosed with a chronic disease.
As a joint venture, physicians and patients must communicate concerns of the drug
regimen, therefore, it is necessary to query healthcare providers on their assessment, perceptions
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and experiences with their patients. Patients and providers are able to provide new insight on the
effects of the reimportation policy.
Definition of Terms
Reimportation: The importation of goods into a country which had previously been
exported from that country (http://www.merriam-webster.com, Retrieved, 2014).
Adherence: the obedience of the patient to the medical advice (http://www.merriamwebster.com, Retrieved, 2014).
Non-adherence: a lack of adherence (http://www.merriam-webster.com, Retrieved,
2014).
Federalism: a system of government suggesting sovereignty is constitutionally divided
between a central governing body and constituent political sub-units (states or provinces)
(http://www.merriam-webster.com, Retrieved, 2014).
Proclivity: often choosing or do something regularly; an inclination or predisposition
toward a particular thing (http://www.merriam-webster.com, Retrieved, 2014).
Chronic Disease: along lasting condition that can be controlled but not cured
(http://www.merriam-webster.com, Retrieved, 2014).
Drug Tiers: categories in which drugs are assigned to one of four or five category
sections (copayment or coinsurance tiers), based on medication usage, clinical effectiveness and
cost (Blue Cross-Blue Shield [BCBS], Retrieved 2014).
Grounded Theory: consist of a theory that is inductively formulated from work gathered
in the field from real world experiences, emerging from researcher’s interviews and
observations; often used in qualitative approach methodology (Patton, 2002).
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Assumptions
Qualitative researchers assume deep understanding and rich description are indication of
the methodology. This research study believes reality is looked upon as subjective and that
environments of social realms are personal constructs generated by individualism and are not
generalizable (Velez, Retrieved 2014). These thoughts are grounded in constructivism and not
positivism. It is assumed not to be a generalizable reality that is quantifiable for larger
populations. Qualitative researchers also believe that exploration is guided and developed by the
values of the researcher along with the hypotheses, theories or the framework being utilized.
Context is crucial, and one can assume that without an exquisite comprehension of the
contextual nature of an exploration project the investigative data cannot be categorized as
generalizable (Sechrest & Sidani, 1995). Pluralistic, interpretive, and open-ended is the desire,
along with contextualized perspectives (Creswell & Miller, 2000). The integrity of this research
was built upon a platform of trustworthy responses from the informants; it was the assumption
that participant’s willingness to participate in this study will result in veracious responses.
Limitations
The study is limited to a population from only one state. The state of Maine is the least
dense state in the Northeast region of the United States and ranks 2nd behind Vermont as having
a population predominantly of Whites, 95% (Long, 2012). Therefore, the study does not
represent other entities of race and demographic regions. With a focus on chronic disease
patients, the study cannot theorize for the experiences of participants having various other acute
diseases. Therefore, nonadherence and reimportation effects and perceptions of these diseases
remain to be seen. Maine’s new reimportation policy and implementation tenure are short (only 1
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year) and perhaps not enough time has passed by to see the true effects of this legislation. It is
possible that this research could yield additional and beneficial data by repeating the research
study in 2-4 years into the future.
Significance of the Study
The research is timely since it allowed access to a population (Maine) that is first and
only in the nation to adopt such reimportation drug policies. As of October 2013, Maine has a
population of approximately 1.3 million citizens. This equates to approximately 41.3 citizens per
square mile, making Maine the least dense state in Northeast region (Census.gov, Retrieved
2014). The majority of Maine’s population (75%) dies from just a few chronic diseases: cancer,
diabetes, chronic lung disease, and cardiovascular disease (CDC, 1994). These diseases also
cause major disabilities. On a national scale, 1out 10 Americans suffers from these four chronic
diseases (CDC, 1994). Research is needed to explore options to assist patients with chronic
diseases in order to provide better living conditions now and long-term.
Significant knowledge could be gained from this population that can be replicated
nationwide. This proposed study included data from a population on nonadherence of
prescription drugs and the reimportation policy effects. The results of this study presented new
data not seen by any other state because of null reimportation policies. The state of Maine is
precedent in this manner and this research study has presented new data, new insight to drug
reimportation. Also, allowing for continued dialog of the topic with the intent to generate
discussion for the implementation of new healthcare policies.
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Scope of Study/Delimitation
The research study was conducted with adult, chronic disease patients and providers with
access to the new reimportation policy in Portland, Maine (patients) and state-wide (providers).
Adults with an age range of 18 years old and older were solicited; conformation of age was
achieved via demographic profiling within the research questionnaire apparatus. The research
had a total of 20 participants: 10 patients and 10-providers. The adult participants were
diagnosed with a chronic disease and have a continuous regimen of prescription drug refills.
Healthcare providers such as physicians, nurse practitioners, and physician assistants were given
questionnaires for their perceptions of this policy. The exclusionary and inclusionary decision
process performed during the development of the study identified boundaries of the research
topic. The initial delimiting step was choosing the research topic, implying that all other related
research concerns have been rejected. Both genders men and women were considered and a
diagnosed with a chronic disease was confirmed. The apparatus used to collect data was
questionnaires/interviews; these questionnaires were used to make several distinctions. The
geographical placement of the study is unique and can only be performed in one locale (Maine).
Therefore, it was critical to visit Maine to capture vital information and observe non-verbal cues
that cannot otherwise be observed.
Implications for Social Change
Pharmaceutical drugs are the most socially important healthcare product, having
influences in every healthcare facet. As of 2012, the United States had 312 million citizens
(Census.gov, 2014). Most individuals will be affected by pharmaceutical drugs at some point in
their lives. From time of birth and throughout life, drugs play an important role for good health
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and enhancement of quality of life. Childhood immunizations have eradicated many previously
life-threatening diseases, and individuals continue to use drugs throughout their lives. The entire
population is affected directly and indirectly. Cost-related nonadherence is a significant factor
for continued health problems and rising healthcare costs. Consumers of any product or service
will typically make the most economic, cost saving decision before making a purchase; drug
purchases are no different. Keeping reimportation in the forefront can allow for many officials,
various healthcare departments to unite and figure out a logistical process for ensuring safety and
quality. Reimportation drugs can surmount to a healthier population while contributing to a
significant savings to the healthcare system.
This research study addressed real-world applications within the healthcare arena. It
contributes to strategies that can be implemented to enhance patient adherence of their drug
medication regimen. As seen in the state of Maine, this research desired to foster new dialog that
contributes to national policy change. With current national policies and the continuous high cost
of drugs, there exists a social problem that has been greatly overlooked. The action of
reimportation (as a contributing remedy to increasing adherence) will significantly contribute to
positive social change to a population which relies on these drugs but have limited access due to
the significant high cost. Reimportation policies can have a significant impact on healthcare
prescription savings with long-term health care savings, due to drug adherence. This increase
adherence can decrease chronic diseases from getting to a worsen state, that requires additional
medical treatments and cost.

13
Summary
Due to the social economics, cultural and the structure platform of the pharmaceutical
industry (its ability to control pricing) the United States’ healthcare system has created and
sustained cost-related nonadherence that has contributed to an increasingly worsen state for
chronic disease patients. Their inability to afford much-needed drugs has forced patients to not
adhere to physician’s orders for medication regimen. Unfortunately, the outcome results in
higher medical costs, decrease quality of life and an issue that is perpetuated without any resolve.
Senior citizens are affected more due to their social economic status and insufficient medical
insurance coverage. The general population will (in time) demand safe, affordable drugs whilst
current policies are deficient in delivering the demands of a nation. Organizational change is
needed to create and sustain safe new policies while changing the mindset of political officials
and healthcare officials granting patients safe and cost saving drugs which may contribute to
their ability to become increasingly adherent.
The literature review in Chapter 2 presents details of factors contributing to drug
nonadherence, cost comparisons, contrasting information on the European pharmaceutical
system and reimportation concerns and details. In Chapter 3, I described detail of the design for
the research study using qualitative grounded theory methodology. Chapter 4 outlines the results
of the data collected from participants in Maine. I presented the results of memoing, opinions,
feelings, and perceptions of the informants. In Chapter 5, I presented and explained the findings
of the research.
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Chapter 2: Literature Review
Introduction
Several studies have been performed in relationship to patients’ non-compliance of their
prescription drugs regimen. Also, existing is a plethora of data (pros/cons) for reimportation of
prescription drugs. Current federal laws of the United States will not allow any state to reimport
prescription drugs; therefore, research has been quite limited. But the situation is changing, a
new ruling (first of its kind) in the state of Maine allows direct purchases of mail-order drugs
from foreign pharmacies (Levitz & Martin, 2013). The new policy took effect in October 2013.
Literature gaps are present regarding research concerning reimportation of drugs as one
corrective component to patients’ mandated drug regimen. This research explored this topic and
provided research data to the study.
Research is needed to understand and explore the impact of pharmaceutical reimportation
drugs in relation to patients’ non-adherence conduct; accomplished by studying the one and only
state that has legislation in place. Maine’s population is free to reimport pharmaceutical
medications and does not have to participate in any clandestine activities or be in fear of punitive
repercussions. Thus, there exists a completely different mindset among this population (that is
not found in other locales) that could render valuable information on the topic.
The purpose of this study was to research the perceptions of drug reimportation policy on
chronic disease patients in the state of Maine and the influences of said policy as it relates to
drug adherence. The study further explored optional corrective measures for patients’
medication regimen and interpreted the perceptions of the participants from the data collected.
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This chapter discussed the demographics of Maine’s population, local and national
diabetes prevalence, and reimportation current stance. Additional discussion consisted of
adherence measurements, and a specific population who is having difficulties filling
prescriptions. Medicare Part D along, with a preventive healthcare model is discussed. Further
discussion of drug cost determinants, long-term health costs, and a brief overview of the
pharmaceutical industry while addressing some political voices, FDA rulings and gaps within the
literature.
Literature Review Proper
Non-adherence is a topic of heavy discussion within the healthcare arena. It is a key issue
concerning the plight of patient care. Patients often state more prescription use (adherence) to
their physician than what actually occurs (Karmel, 2005). In a compliance study performed by
Dr. Michael Kass (published in 1986) he discovered a large discrepancy between self-reported
adherence 100% and the true value of 76% (Karmel, 2005); and the problem still persists today.
Most patients blame the increased cost of drug as the problem for their non-adherence; this is
known as cost-related non-adherence (CRA).
Some reports for reimported drugs thus far are indicating significant savings to the
citizens of Maine. For example, utilizing a Canadian broker (CanaRX) the city of Portland,
Maine pays approximately $200.00 for a 3 month supply (with no co-pay) of Nexium; Nexium is
a heartburn medication regulating at a 40 mg dose per tablet. The same exact Nexium medication
through Aetna Insurance Inc. (USA) is at $620.00 and has a co-pay of $156.00 (Levitz & Martin,
2013); that is a savings of $576.00 to the patient and the healthcare system. Many other
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medications fall under similar savings, therefore, the overall cost savings to the healthcare
system would be enormous.
Karmel (2005) looked at a meta-analysis of 569 studies that observed prescriptions of
non-psychiatric physicians, this study had a 25 % non-adherence rate; the study also revealed a
30% non-adherence rate for silent conditions such as diabetes and pulmonary diseases that
demanded long-term and complex drug regimens. This research study focused on the chronic
disease patients for Maine’s population and their nonadherence conduct. Early reports from
Maine are already indicating cost savings. A spokesman for a private firm in Maine has stated
that access to international pharmacies has reduced its annual health-care spending cost up to
$600,000 (Levitz, 2013).
Because of the esoteric nature of Maine’s policy and its genesis stage, I explored various
factors that would yield information on the pharmaceutical industry, the political arena, and
culture and socioeconomics aspect of reimportation. The literature mining also explored longterm cost saving, the federal law stance and briefly contrasted foreign pharmaceutical markets to
the United States markets.
Literature Search Strategies
A search of several electronic databases with respect to patient drug non-adherence, and
drug reimportation included Google Scholar, Proquest Health and Medical Complete, Proquest
Central, EBSCO, ERIC, Medline, Government websites (FDA, CDC and others) various
university school libraries and the reference section of reviewed articles; all terms were entered
into each database. Keywords and phrases used within each database included; patient drug
compliance, patient drug non-compliance, patient drug adherence, patient drug non-adherence,
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reimportation bill, Maine reimportation law, and chronic disease; Canadian exports of drugs,
drug tiers, pharmaceutical intellectual property, preventive healthcare, European
pharmaceutical markets, generic drugs, reimportation safety, grounded theory and FDA
reimportation.
Basic economics can justify decreased pricing of products and services when consumers
are given a choice, and competitive markets are applied. Applying this theory to the
pharmaceutical system and making a connection that increases patient drug adherence has yet to
be seen. And, this is not surprising because the (United States) has not allowed legal
reimportation of any pharmaceutical drugs thereby studies of reimportation drugs and patients’
adherence are void and null. Literature of variables, reimportation and adherence, is not
supported within the literature review. Thus, it is imperative to capture data and study this new
policy and learn of the affects it is having on a given population.
Gaps in Literature
Research literature exist on patient drug adherence and non-adherence; there also exist
literature on cost of drugs and the affordability (or the lack thereof) but there are literature gaps
concerning research that provide a link to reimportation of drugs as a corrective measure for
patients’ non-adherence. Literature gaps are to be expected due to the current policies and the
denial of reimportation drugs into the United States. It is imperative to explore the only state that
has policies in place for reimportation of pharmaceutical drugs.
Asking if and how reimportation affects patients’ adherence is completely valid, it has yet
to be determined. The literature is void to null on the affects (if any) that these variables have to
each other. It is the hope of this research that federal enforcements (FDA & others), lawsuits and
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any other antagonistic efforts do not interfere with reimportation efforts and that this topic can be
transitioned to other states. The tempestuous discussions of reimportation should keep the topic
in the forefront of political officials and the general public.
Pharmaceutical drugs (without a doubt) are the most socially required healthcare
products. The integral role affects every facet of healthcare and the quality of life for patients;
this is evident from the many diseases that have been eradicated by drugs that previously killed
many individuals worldwide (NAPSRx, 2013). Cleemput and Kesteloot (2002) stated that nonadherence is an important factor of impediment to the effects of health interventions; gaps exist
between efficacy and effectiveness due to non-adherence.
This qualitative study explored the perception and mindset of individuals who were once
clandestine in their efforts to acquire inexpensive drugs from foreign markets and what affects
are being displayed with this new found freedom. Therefore, many gaps exist and much
knowledge awaits future researchers who take on the pharmaceutical industry and challenge
them to provide more affordable drugs and keep in mind the financial distresses that many social,
and economic hardship patients have.
Theoretical Foundation
This exploration is built upon Lewin’s (1947) theory of organizational change. It
proposes a thought process that could be utilized for federalism change. Kurt Lewin (1890-1947,
social psychologist) whose work involved studies of leadership and their effects that focused on
three distinct stages of change management: (a) unfreezing, (b) change (transition) and (c)
refreezing he suggested unfreezing is the method that involves locating a process to make
possible for people to relinquish old habits and patterns that proved counterproductive.
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Levels of resistance and group conformity must be unfrozen in order to allow forward
progression to a new stage; thereby incorporating change (transition) in thoughts, feelings,
behaviors, or all three that result in liberation and increase productivity. Lastly, refreezing puts
into place the newly accepted change into a new accepted habit. It now becomes standard
operating procedure (Morrison, 2014). It is easy to revert to the old habits without this
implementation of refreezing. Adaptation and implementation of new policies is built upon this
framework. Organizations, leaders, and others must acknowledge a new mindset which is
imperative to employ new national legislation related to prescription drugs. Many processes and
strategies could increase the chance of health policies and programs to be adopted and enforced
within formal institutions (Kritsonis, 2005).
Demographics-Maine
As of 2013, Maine had a population of approximately 1.3 million citizens; this equates to
approximately 41.3 citizens per square mile, making Maine the least population-dense state in
Northeast region (Census.gov, 2014). Maine’s age-distribution is somewhat out of balance stated
Professor Colgan an instructor at the University of Southern Maine’s Muskie School of Public
Service (Colgan, 2014); the oldest national status shows a median age of 43.5 y/o according to
2012 U.S Census Bureau; this is an indication that half of Maine’s population is older than 43.5
y/o and half is younger.
Maine trails only the state of Vermont in having the lowest percentage of citizens under
the age of 18. The Census department estimates that Maine has approximately 411,540 citizens
between ages of 45 and 65 while another 301,124 citizens are between 20 and 39 years of age
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(Census.gov, 2014). In 2011 and 2012 for the first time in 70 years, more people died in Maine
than were conceived according to Maine’s Office of Vital Records (Maine.gov, 2014).
High Disease Prevalence
Seventy five percent of Maine’s population dies from four chronic diseases: chronic lung
disease, cardiovascular disease, diabetes, and cancer (CDC.gov, 1994). Maine’s chronic disease
prevalence is in alignment with national levels. According to the CDC, as of 2012,
approximately 50% of adults (117 million people) have one or more chronic disease(s) health
conditions. Over a fourth of adults have two or more chronic health conditions. Seven of 10
reasons of death in 2010 were related to chronic diseases. Heart diseases and cancer combined
accounted for nearly 48% (half) of all deaths (CDC.gov/chronic diseases, 2014) and diabetes is
the primary cause of kidney failure that often leads to death. In addition to killing 75% of
Maine’s citizens, these diseases also cause major disabilities. This is comparable to the national
scale; for 1out of 10 Americans. These four chronic diseases contribute to limitations of daily
activities (CDC.gov, 1994). Therefore, it is significant to research options that can alter the plight
of patients’ living conditions now and long-term.
Diabetes Maine
Although the research consisted of patients with various chronic diseases, diabetic
patients display high numbers of non-adherence in the United States and regionally in the state of
Maine. Prevalence of pre-diabetes has remained steady yet diabetes among the population of
Maine has steadily increased over the years staying in line with increase rates of the United
States (Maine.gov, 2014). Utilizing data from the Maine Behavioral Risk Factor Surveillance
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System (BRFSS) data is collected from random adults with chronic related diseases and injury;
each year over 6,500 Maine adults participate in this survey (CDC.gov, 1997).
Pre-diabetes among males and females are very similar for survey years 2008 to 2010
(Maine.gov, 2014). According to state records, 7.4% of its population has diabetes; this ranking
is 20th of 51(among other states); that equates to 6.6 adults out of every 100 adults having
diabetes. Furthermore, for every 100,000 citizens there were 27 deaths related to diabetes in
2002 (CDC.gov, 2014).
Diabetes Type II
WHO (2003) suggested poor adherence to the regimen for diabetes resulting in avoidable
pain and suffering for patients that translates to excess healthcare cost. In a World Health
Organization study in Europe, only 28% of patients treated for type 2 diabetes achieved good
controlled glucose levels (WHO.gov, 2003). The study stated that the control of diabetes
requires more than consumption of medicine, suggesting that change of diet, monitoring of blood
levels and eye examinations are required. In contrast, the study noted that in the United
States<2% of adults with diabetes performed the full level of care as reported by the American
Diabetes Association; among one of the reasons for this was economic costs (WHO.org, 2014).
United States Reimportation Bill (2000)
Competing proposals to aid Medicare beneficiaries pay for medicine (Dewar, 2002) is an
ongoing discussion. The process of allowing drugs produced in the United States, to be shipped
out of the country and returning to its origin (reimportation) remains elusive in today’s
healthcare system. Current legislation remains inactive and necessitates certification from the
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Health and Human Services Secretary (HHS). Until such processes, the United States will be
devoid of cost benefits and savings to the healthcare system from a national reimportation policy.
Federal Drug Administration/Federal Ruling
Several safety concerns are noted within the import revision of the Federal Food, Drug,
and Cosmetic Act (FFDCA) that vigorously limit types of drugs that can be imported into the
United States. Several concerns from the FDA exist; for example it is unclear whether overseas
pharmacies exporting prescription drugs would follow the United States’ federal laws that
protect privacy. Under any proposed mandate, states have no mechanism in place to ensure
foreign pharmacy compliances, thus physicians, pharmacists, and patients are unable to judge
properly whether products are safe and effective (FDA, 2014).
The FDA is also concerned with labeling of products and a lack of logistical recall
procedures in place; there are no practices to ensure that only FDA approved products are
shipped. Several other concerns are listed, and discussions for each can be quite overwhelming
yet many believe that now is the time to take a closer look at reimportation.
United States Pharmaceutical Industry/Intellectual Property
Arfwedson (2014) suggested that reimportation is the protocol whereby drugs are
protected by intellectual property rights (IPR); for example patents, copyright or trademark) and
these drugs are placed into market circulation and then reimported to another market (without
authorization of owner). The argument extends to both sides of the aisles with some stating that
the reimportation undermines intellectual property that decreases re-investment opportunities;
while others state the decreasing cost of reimportation drugs benefits their citizens. Intellectual
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property rights (IPR) (although limited) are conveyed by the state for certain ideas, expressionsproducts of intellect.
Because IPR is conveyed by state mandates, their existence has limited barriers that are
bound by a geographic barrier. But many states implement “principle of national exhaustion”
that states IPR holder’s rights are extinct upon first sale within national borders. In contrast,
international exhaustion terminates rights upon first sale anywhere and reimportation may not be
excluded (Arfwedson, 2014). Exhaustion policies vary in many ways and within different
countries.
In the United States, the first sale mantra applies when purchased outside a vertical
distribution chain (Thomas, 2007). Reimportation of pharmaceutical drugs are admissible, in
order to block and trademark owner needs to show that imports are not identical in quality to the
original products. Currently, there is no legally binding global consensus pertaining to
exhaustion of intellectual properties. The closest concept we have to a global agreement is the
Trade-Related Aspects of Intellectual Property Rights (TRIPS) that is govern by the World Trade
Organization; TRIPS provides very limited intellectual rights standards therefore limited
protection (WHO.org, 2014).
Pharmaceutical Lobbyist-Opposition
With such large profits, it is no surprise to see drug companies in opposition for new
policies that would infringe upon their closed markets. Hess (2002) indicated that The
Pharmaceutical Research and Manufacturer of America (PHrMA) has voiced its opposition to
reimportation. He (Hess, 2002) also stated that the drug industry has spent well over $40 million
to dispute new legislations that could promote reimportation. Senator DeLauro (D-Conn) stated
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that current policies allows drug manufacturers a way around the processes that undermines the
entire system (Hess, 2002) due in part to having a strong representation (lobbyist group)
assembled in Washington D.C.
Reimportation National Stance-In Favor
Reimportation of prescription drugs continues to gain national support at various political
levels; a system called reimportation due to many products origins and is produced in one locale
(country), shipped to another locale (outside the country) and is then returned to original locale
where it is sold at a discounted price. Broader reimportation legislation was addressed yet one
caveat to this legislation (within the body of the policy) was that it must be certified by a sitting
Human Health Secretary (HHS). Former Human Health Secretary Donna Shalala did not certify
it therefore (reimportation policies) never took effect (Lueck, 2002); there exist an inactive, nonenforceable law on the books as it relates to reimportation. Many Americans fail to realize that
such a bill exist and was (also) signed by former President George Bush but again certification
from then Secretary of Health and Human Services Tommy Thompson eluded the process and
the non-certified process has repeated up to current day thus, no national reimportation policy.
Arias (2003) stated that Canadian processes for labeling, distribution and handling
prescription drugs are safe and also stated that in many instances the process was even safer than
the United States. Outspoken leaders from both sides of the aisle agree that safety must come
first. Arias (2003) noted that the cost comparison of drugs between Canada and the United States
are quite substantial. Several leading companies in the private sector are advocates for such
measures, for example, The America Association of Retired Persons (AARP) has long favored
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reimportation as they showed support for a bipartisan bill introduced by Senators Snowe (R-ME)
and Senator Stabenow (D-MI) (Moscovitch, 2011).
One of the largest pharmaceutical retail distributors (CVS) has also indicated support for
reimportation. CVS (based in Rhode Island) operates over 4,100 pharmacies nationwide; they
were the first major drug store chains to support drug reimportation (Ryan, 2004). High ranking
officials in many states also have stated their support for this matter and some 20 state attorneys’
general in various regions has indicated high support for drug reimportation. Other supported
documentation has been established by Representative Ron Paul, his bill indicates a possible
savings of nearly $20 billion from the Congressional Budget Office with the implementation of
drug reimportation (Congress.gov, 2014).
DeAgostino (2004) stated that a reimportation bill would pose no safety risk and that the
reimportation in Europe is very common and safe; facts indicate that reimportation of drugs has
been done for over 20 years in Europe. The United States’ healthcare system has made attempts
to soften the high price of medication but to no avail. Democrat Kernan and Republican Daniels
support drug reimportation if the government is unable or unwilling to curb high prices.
Because of high prices, many cities throughout the nation are considering looking to
Canada for prescription drugs. Boston Mayor Thomas Menino announced a pilot program that
will lower cost of over 7,100 employees and retirees of the state (Austin American-Statesman,
2003). The state of Minnesota is setting up a website while West Virginia and Illinois look to
reach out to Canadian brokers as well.
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Reimportation National Stance-Against
There is no shortage of contrasting voices on reimportation, many officials have a
common say in the matter and safety is the main concern. Former Department Health and Human
Services Secretary Tommy Thompson stated that he could not vouch for the safety of drug
imports and felt that any savings would be limited (Dalmia, 2003). Further discussion suggests
that removing protection barriers for drugs could invite U.S. patients to counterfeit, dangerous
medicines, and adulterated drug products (PR Newswire, 2000). For every region of political
representation there are those who oppose reimportation; many political officials echoing the
voices of the people in their political regions.
Safety concerns continue to block efforts to streamline drug reimportation programs
Arias, (2004). Officials agree that safety must come first when purchasing prescription drugs.
Speaking to the U.S. Newswire Dr. Matthews stated reimportation is a safety issue but also
suggested that it is a job issue as well. Local communities across America would suffer due to
the outsourcing effects reimportation has on local economies.
Reimportation-Maine’s Stance
Under Maine’s Labor, Commerce, Research and Economic Development distributed by
direction of the Secretary of the Senate the state of Maine Senate 126th Legislature First Regular
Session implemented “An Act To Facilitate the Personal Importations of Prescription Drugs
from International Mail Order Prescription Pharmacies” (Maine.gov, 2014); in short, this is
Maine’s, reimportation policy. The first in the nation to allow its citizens to import prescription
drugs from foreign markets.
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Many are inclined to assume that the drugs are coming in from Canada (solely) but this
legislature allows for imports from Northern Ireland, United Kingdom of Great Britain, New
Zealand , and The Commonwealth of Australia that meet that country’s regulatory and statutory
requirements (Maine.gov, 2014). Maine has stepped into the forefront as it battles the increase
cost of prescription medications. Along with this new policy other programs have been
implemented to aid the cause. “Health Maine Prescriptions” utilizes the purchasing power of
Medicaid to give up to 25% discount to lower income individuals (Toner, 2002); Maine is
ground zero but this is a national issue. Surprisingly there are advocates on both sides of the
aisle. Pugh (2004) stated Republicans find the idea appealing, and the number is growing who
support reimportation.
Patient Non-Adherence
Basskin (1998) suggested one should consider asking several questions to get to
the root of the cause of non-adherence. For example, is the reason for nonadherence preventable
or avoidable? Does improving compliance improve outcomes? To what degree does a specific
intervention improve adherence and is the intervention cost effective? Patients have an ongoing
responsibility to seek help and to confide with their physician/providers to help quail this
problem.
The additional consequences of nonadherence with prescription drugs are documented by
many studies. Frost & Sullivan (2006) has indicated that in the United States patients’
compliance with long term pharmaceuticals medication has an average of only 50 percent;
estimation of nonadherence to pharmaceutical medication causes nearly 125,000 deaths per year.
Also, according to Frost & Sullivan (2006), approximately 10% of hospital admissions and an
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estimated 23% of patients in a nursing-home are due to drug nonadherence. Some one-third of all
drug prescriptions are never filled, and more than (50%) of prescriptions that are filled are
incorrectly administered.
The results of poor adherence are seen as the burden of chronic illnesses increases
worldwide. The outcome of poor adherence to long-term treatments results in poor health
outcomes while increasing the cost. Improving adherence also enhances the safety of the
consumer. Effectiveness of adherence could possibly have increase implications healthconditions of the population than any other medical treatment; as a nation, health systems must
step up to the occasion (WHO.org, 2003).
Compliance vs. Adherence
The new preferred term is adherence although often interchangeable with compliance a
more definitive reference has been established for the terms. Compliance (original term) implied
that patients following doctors orders. Adherence (appearing later in literature) refers to active
patient participation and a doctor-patient partnership (Karmel, 2005) - this term allows for
patients to assume more responsibility for their care.
Adherence Measurements
Throughout many years non-adherence of 25% or greater have been monitored and
measured through patient self-reporting, reports of prescription refilling, electronic monitoring,
and with open-ended questions to patients (hoping for truthful responses). The World Health
Organization (WHO, 2003) suggested one measurement approach is to ask providers on
adherence behaviors, but there seems to be a tendency to overestimate their adherence. Simply
counting remaining tablets can be performed at the clinic however inaccurate counting is very
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common. The WHO states that there are no definitive ways to assess specific behaviors that are
reliable to predict adherence.
Patients Who Fill and Not Filling Prescriptions
Several studies suggest that senior citizens are having the most trouble with adherence of
their medication regimen. A study performed by Shah, Desai, Gajjar and Shah (2013) of 200
geriatric patients (of various outpatient departments) suggested lower socioeconomic status,
complex drug regimens along with the duration of the treatment significantly contribute to senior
citizen’s nonadherence conduct. The research also stated the lack of education is a huge
contribution factor; a United Kingdom study also reflected the importance of education
intervention. Nordqvist (2011) noted an increase in drug cost has taken place along with a
population increasing in age that has lead to significant financial burden to those needing
medication.
Combined with high employment and increase insurance payouts by employees, coupled
with many non-insurers many Americans under the age of 65 find themselves in the same
predicament.
Medicare Part D
The Medicare Prescription Drug Improvement and Modernization Act 2003 (MMA)
represented a greater expansion of benefits to over 42 million senior citizens. Activated in 2006,
the program gave access to prescription drug benefit (Part D). The program gave rise for the
need of improved drug coverage and opportunities to mitigate increase drug costs.
Five key elements for Medicare were realized in recent years, information obtained from
a 2003 national survey conducted by Saran, Neuman, Schoen, Kitchman, Wilson, Cooper,
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Chang, and Rogers resulted in the importance of prescription medicine in the healthcare system
of the United States and the effects it has on elderly citizens. Secondly, the United States has
over 40 percent of low-income citizens who lack insurance in several states. Third, Medicaid has
had a positive role and moving patients over to the new Part D plans is essential; forth we see
that not all plans are equal and that variances exists from state to state that requires extensive
education, outreach and enrollment strategies (Saran et al., 2003).
Finally, the increased rates of nonadherence to prescription medications due to costs and
other factors indicates that the new Part D plan may be of benefit in this matter in limited form
but other nonadherence factors may need to be addressed via doctor/patient interactions and on a
larger scale within the healthcare system (Saran et al., 2003). In a Consumer Report’s survey
(2012), 62% (<65 y/o) declined medical test due to cost, 45% skipped filling a prescription due
to high cost, 63% put off doctor’s appointments and 51% skipped a medical procedure; over 81%
of the individuals said they had done at least one of these steps due to financial burdens (Morran,
2012). One finding from the survey was that many consumers did not confide with professionals
who could aid them. For example, the physician could have provided sample medication or
offered coupon incentives from the drug manufacturer. Medicare is the largest purchaser of drugs
in the world’s largest market. By law, Medicare is prohibited to locate better prices. Getting
Medicare to seek more affordable pricing would save the federal government $137 billion over a
ten year period, according to the Congressional Budget office (journalinquirer.com, 2013).
Preventive Healthcare
Public health and preventive medicine is guided by preventing diseases, promoting
health, and managing the health of the community and populations. Health officials combine
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public health skills, population, and knowledge of primary, secondary, and tertiary preventionoriented clinical practices in various settings (theabpm.org, 2014). Increase patient drug
adherence can provide a better outcome that can better reduce the chronic aspect of a disease;
decreasing the more serious characteristics of long-term diseases; thus, overall healthcare savings
would be seen having a better outcome for the patient (theabpm.org, 2014).
Another factor is patient/provider partnership-the extent in that patients and providers
agree, adherence requires the patient to believe there is a beneficial component to taking
medication; there cannot be any barriers and open communication is important, this comes only
with time (AmericanCollegeofPrevention.org, 2014).
Pharmaceutical Drug Cost Determinants
Determinants of drug cost from originator branded drugs across various regulatory setting
and health care systems differ in many ways. For example, release date of the drug can play a
significant role in pricing along with patent status and marketing techniques (Kanavos,
Vandoros, 2011). Distribution margins for generics and new medication hitting the market
contribute to price formation throughout the country as well.
Kanavos, Vandoros (2011) stated exchange rates of countries and the volatility of the
market can make a grave difference on pricing. But in the United States one must not forget
about taxes and logistical factors that inflate pricing. Prices of branded medication do not
necessarily decrease because of exhausted patents and the release of generic drugs.
Reasons for High Cost
Many reasons can account for high drug cost in the United States; it is heavily
documented that the pharmaceutical industry is allowed to set their prices (no government price
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regulations). Zall (2001) noted Pharmaceutical companies intend to recover their entire costs and
produce a profit. In order to recoup all the costs associated with research and development along
with marketing, pharmaceutical companies will charge what the market can bear; that market is
the consumers they serve. For example, mass advertising is fairly new, the process seems to be
designed to appeal directly to consumers. The nation’s pharmaceutical companies spent $1.3
billion in previous years and recouped the cost in sales (Lancaster New Era, 1999). The
Lancaster Business Group on Health stated that increases in insurance premium along with
increase co-pays contribute to this issue as well; most companies saw a 12-20 percent increase
that will continue to rise.
Swatz (1995) stated that the very high cost of research and development that exceeds
$350 million per drug is why companies insist on 20 years patent protection, this helps drug
companies to hold on to the drug and recoup costs. Kana, Ferrario, Vandoros & Anderson (2013)
suggested that US per capita pharmaceutical spending has a rapid uptake of newer and pricier
drugs in the United States in comparison to other countries. Simply put other countries require
drug companies to provide strict evidence of the value of the new drug, the United States does
not. Paul, Chandra & Lambrinos (2006) suggested that insurance has made drugs more
affordable thus, increased the consumption and cost of pharmaceutical drugs.
Long-term Healthcare Cost
Lueck (2002) wrote that Americans could have saved $38 billion in 2001 if Americans
were allowed to make prescription drug purchases from Canada. Quon, Firszt, & Eisenberg
(2005) performed a comparison of 44 brand drugs to the Canadian markets and concluded that
Americans can save a mean of 24% if drugs were purchased from Canadian internet pharmacies;
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stating that brand drugs are substantially less expensive. Savings is a two-fold concept in that
direct purchases contribute significantly to healthcare savings and the affordability would lead to
an adherence factor that would increase better living conditions and decrease the chance of
diseases elevating to a worst state.
If one was to consider nonadherence alone, Frost & Sullivan (2006) suggested that
nonadherence contributes to $100 billion (direct cost) to the United States’ health care system.
Indirectly costs exceed $1.5 billion yearly due to the lost of patients’ earnings and unrecoverable
productivity ($50 billion). The nature of this issue has prompted the National Council on Patient
Information and Education (NCPIE) to term nonadherence as "America's other drug problem".
Adherence Comparison; Canada vs. USA
Although the emphasis is on drug prices in the United States, we see problems in other
nations having similar healthcare issues to tackle. In the United States and Canada patients
having trouble funding their medication drugs are more likely not to adhere thus, risking increase
illnesses and death while increasing healthcare cost (Kennedy & Morgan, 2006).
Kennedy & Morgan, (2006) indicated in a joint Canada and United States survey (20022003) by the Statistics Canada (Ottawa, Ontario, Canada) and The U.S. National Center for
Health Statistics (Hyattsville, Maryland) consisting of 3,505 citizens in Canada and 5,183 in the
United States reported that residents of Canada are less likely to report cost-associated
nonadherence (5.1% vs. 9.9; P< 0.001). The report goes on to say that Americans having no
insurance (28.2%) and Americans & Canadians with no prescription coverage (16.2%) were
more likely to report cost-related nonadherence. The conclusion of the survey stated the general r
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cost-associated nonadherence is greatly higher in the USA (even with the availability of health
insurance and pharmaceutical coverage (Kennedy, Morgan, 2006).
Drug Tiers
Regardless of the paying entity such as private insurance company, Medicare, Tricare,
Medicaid and other programs they all maintain a list of pharmaceutical drugs that they will pay
out known as formulary. Formularies are comprised of prescription drugs, generic drugs, and
often times over-the-counter medication (OTC) that were prescribed. It (formulary) is structured
in such that they vary in co-payments. Torrey (2014) gave a summation of Tiers 1, 2, 3 & 4:
Tier 1 or (I): Drugs are limited to generic brands- they are the lowest price drugs. Many lower
prices branded drugs fall into this tier. Tier I drugs co-pays range from $10 to $25.
Tier 2 or (II): This tier usually consists of branded name drugs and/or more expensive generics.
Tier II drugs have value co-pay, ranging from$15 to $50.
Tier 3 or (III): For more expensive brand name drugs, (most often not the first choice for your
insurance company because of increase cost) they are also known as non-preferred. Tier III drugs
cost are more than the lower tiers, having a range of $25 to $75 co-pay.
Tier 4 or (IV): Known as specialty drugs: newly approved pharmaceutical drugs, and are so
expensive that insurance companies will discourage patients from obtaining these prescriptions
drug. Tier IV is a newer designation, initiated in 2009; tier IV designation seems to categorize all
other expensive drugs. Co-pays are assigned a percentage and not a dollar amount.
Motheral & Fairman (2001) suggested that the three-tier drug co-pays can control cost
without confirmation of changes in other regions of medical resources.
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Generic Drug Benefits
Many costs saving measures have been attempted to ease the cost of drugs. Physicians
often give out sample drugs to individuals who are having trouble paying for their prescriptions.
Pharmaceutical companies have initiated programs to assist consumers who by high cost are
burden. The government has even stepped in to promote generic drug production while
decreasing the time to get generic drugs to market.
The Hatch-Waxman Act also known as the Drug Price Competition and Patent Term
Restoration Act of 1984 is the most enhance drug-related legislation linked to the pharmaceutical
and healthcare industries since the early 1960’s. This act made it faster and easier to bring
generic prescription drugs to market by mandating the FDA to only look at bioavailability
studies in order to approve the drug known as the Abbreviated New Drug Application (ANDA).
ANDA allows a 30-month cooling off period for challenges of patent infringements (NAPSRx,
2013). This measure helped encouraged the increase of generic drugs over branded drugs, faster
development, along with quicker delivery to consumers.
Dr. Emanuel (2012) stated that the cost savings can be achieved by substitution (using)
generic drugs. During the years of 2004 to 2009, the use of generic drugs for branded drugs
increased to 75% from previously 57%. In 2010, the United States spent an estimated $262
billion of prescription drugs equating to approximately 10% of total healthcare expense $2.6
trillion (WHO.org, 2014).
Contrasting Markets Using the European Pharmaceutical Industry
For every aspect of this issue (reimportation) the United States should look
beyond its borders and be willing to adopt portions of legislation (from other nations) that
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eliminate unproductive outcomes and promote better quality of life; this is in alignment with the
theoretical framework of Lewin’s organizations change theory that this research has adopted.
Contrasting this market is important for United States’ officials to see that an existing
reimportation model does exist. The European program also reassures the public that no
pandemic or epidemic is occurring as it relates to reimportation of drugs (known as parallel
imports in Europe) lending a sense of security and safety to the masses.
It is significant to note the tremendous savings has been afforded to the European
healthcare system. Replication of this process is possible in the United States with slight
modifications that suites the demographics population and the U.S. healthcare structure. In other
words, there is no need to develop a process from infantile stages when a fairly workable model
exists. It is important to observe the components of their (Europe’s) structure, pricing policies,
and price control strategies.
In the past two decades or so expenditures on pharmaceutical drugs and other healthcare
costs have increased faster than gross national product of all European nations (Ganslandt &
Maskus 2004). European policies are multidimensional and accounts for issues of public
expenditure, public health, and pharmaceutical incentives. Consumption patterns and various
pricing levels determine the total expenditure that varies across the various European nations.
Ganslandt & Maskus (2004), stated pricing policies are generated by product price
control, reference pricing and profit controls. Product pricing control is use in determining the
prices of medication. The vast difference was the introduction of Single European
Pharmaceutical Market that implemented parallel imports (Ganslandt & Maskus 2004). Similar
to the U.S. market several practices have been put into place to control cost of patients’ expense.
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The uses of generic drugs are encouraged, also providing a listing of drugs that are reimbursable
(positive list) or a negative list (one that does not reimburse) including the co-payments of each
drug.
Due to the Single European Market structure it is not surprising to know that countries
reimport drugs from each other all the time. Using data from a Sweden research, prices from
parallel imports decreased in comparison to other drugs over the time period of 1994-1999
suggesting parallel imports (reimportation) decreasing manufactured cost by 12-19% indicating a
saving can be passed on to patients (Journal of Health Economics, 2004).
Political Aspect-Congress
Klein (2014) suggested that many people feel the Affordable Care Act (Obamacare) may
hold the pharmaceutical industry more in line, give the government some leverage of drug
pricing, and allow for reimportation of drugs from Canada. Congress has spoken out on many
occasions; with rhetoric from both aisles the 113th Congress talked about Medicare cuts. They
suggested that billions of dollars could be saved over the next decade if new policies were
implemented. They suggested putting Medicare drug out for bidding, allowing reimportation of
safe drugs and banning “pay for delay” of generic drugs.
The Preserve Access to Affordable Generics Act of 2013-2014 would end brand name
pharmaceutical companies from keeping equivalent generic brands off the market pay for delay.
Yates (2013) suggested reintroduction of Senate Bill-319 (S-319 of the 112th Congress);
sponsored by Senator Snowe (Republican-Maine).The bill will revise provisions governing the
reimportation of prescription drugs (Congress.gov, 2014). Several senators from northern states
are pushing for new policies; the lawmaker’s bill gives permission for U.S. pharmacies and
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wholesalers to resell and buy medication from Canada. Proximity to Canada seems to be one
indicator for these northern states pushing for new legislation.
Federalism
Implementation of such federal policies will require dialog from both state and federal
officials. Federalism in the United States evolves relationships between state and federal
governments of the United States; the American government has evolved from a dual federalism
system to one of associative federalism (Cornelllaw.edu, 2014). This arrangement has various
agents, departments, and trustees of the people constituted with various levels of power. It is a
political concept that has a group of members bounded together by a covenant. The term is
frequently referred to as a level of sovereignty.
In order to improve the plight of patients and improve patient adherence no one single
component will do. When coupled with other programs and policies, reimportation could aid the
situation and allow researchers, physician (and others) to address patient adherence. But first,
there must be a new order of federalism (a system of government in which the same territory is
controlled by two levels of government Cornelllaw.edu, 2014) that will conform to both state and
federal levels of government that will give more sovereignty without repercussions. This
increase power of freedom would allow state levels to take the bold, rogue steps to improve
healthcare accessibility to drugs as seen in Maine.
Better quality of life has always been the agenda and consideration in pharmaceutical
development. It is quite difficult to see the effects if patients are non-adherent. Dr. Kweder
(retired deputy director of the FDA) stated medication can’t work unless it is taken (FDA.gov,
2014). The largest world markets of pharmaceuticals (United States, Western Europe, Japan-
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respectfully) all suffer from a market-place that lacks standardization; this fact contributes to the
complexity of the pharmaceutical enterprise.
As the leader of the world in many aspects, the United States should take the lead at
standardization, development and affordability; thereby new policies are needed. Converting to a
pharmaceutical structure seen in Europe may have many benefits; the parallel import
reimportation structure has worked for over two decades.
Summary
Literature on non-compliance of patients having various chronic diseases has revealed
that the cost is a common theme. Although other factors come to light, several research studies
and surveys have concluded that the cost related non-adherence is a major concern.
The literature review also demonstrated that many voices exist on the topic of
reimportation of pharmaceutical drugs. Research variables “reimportation” and “patient
adherence” is null within the literature review. Because of the opportunity occurring in Maine,
these variables can now be addressed. An important component to this exploration while
underlining a fluid, adaptive approach is the theoretical framework. Lewin’s (1947) theory of
organizational change is a solid approach to what is needed for reimportation adaptation. A
smooth, transient mindset change can be achieved with Lewin’s organizational change; with
emphasis on unfreezing, change, and the freezing approach. This approach allows for releasing
insufficient processes, making a change to a more sufficient process (or policies) and then
locking those new changes into place.
Millions of low-income individuals and senior citizens (with fixed income) cannot afford
the high price of their drugs as evidenced by a 2013 Commonwealth Fund study that stated 50
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million Americans did not fill a prescription due to high costs in 2012 (Hamburg, 2014). Thus,
patient non-adherence will continue until a series of resolutions are identified and executed.
Contributing to this research was a qualitative, grounded theory approach. This
methodology aimed to get a better understanding through field experiences, truthful data
collection, along with accurate conversation feedback (validation-member checking process). It
strived to comprehend how the informants derive meaning from their experiences, and how these
experiences influence their behavior (Creswell, 2007). Chapter 3 outlined how this research was
conducted and described in depth the qualitative methodology used to conduct this research.
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Chapter 3: Methodology
Introduction
After a review of the literature this study focused on two variables: reimportation of
pharmaceutical drugs and cost-related non-adherence (CRA). Several factors contribute to nonadherence of patients’ drug regimen, but cost is relevant to many senior citizens and individuals
with chronic diseases. Briesacher, Soumerai &Gurwitz (2007) suggested that many links exist
between prescription drug nonadherence because of the high cost and social economics, but due
to depression and other diseases. The literature is null as it relates to reimportation of drugs and
increasing patients’ adherence for patients with a chronic disease. Kurlander, Kerr, Krein,
Heisler & Piette (2009) stated that patients who do not comply with their medications for chronic
pain seem to stem from pressures of their economic status, where other patients who selectively
reduce their regimens are driven by their own perceptions, personal beliefs, and moods.
A better understanding of reimportation and adherence is required to improve the plight
of patients with chronic diseases. Therefore, it is important to obtain data from a population
(within the United States) who can legally obtain prescription drugs without clandestine efforts.
Qualitative method and grounded theory were selected for this research in order to determine the
effectiveness of the reimportation policy. The chapter described the rationale for utilizing
grounded theory, qualitative paradigms, complete description of the design, the sample
demographics (population), descriptive of the data collection methods, grounded theory protocol
and ethical consideration for participant’s protection.
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Research Design and Rationale
Reimportation drugs are developed, produced and bottled in the same exact facilities as
domestic drugs, with the exact same labeling. Many people find it quite difficult that the Food
and Drug Administration (FDA) cannot create logistic safeguards to ensure that this process
could be undertaken in the United States. Dayen (2009) suspects a more sinister reason as he
suggested that any reimportation implementation would void the pharmaceutical industry’s
backroom deal with Senate Finance Committee Chair (Max Baucus) and the White House, which
limited the drug industry’s exposure to “losses”. This deal was set at $80 billion dollars over a
ten-year lifespan. Therefore, we have cost-related nonadherence due to the pharmaceutical
industry’s proclivity towards profits.
I selected the grounded theory approach to determine the effectiveness of the
reimportation policy within the study population (Maine) and to gain knowledge of the
perception of this policy on said population. The grounded theory design and qualitative method
are appropriate as suggested by its paradigm of advocacy and participatory characteristics.
Creswell (2008) suggested that this worldview “needs to be intertwined with politics and a
political agenda” (p.9) thereby having an action agenda for reform.
Role of the Researcher
Rudestam & Newton (2001) noted that data gathered from qualitative research is
compiled from various tools: questionnaires, interviews, personal knowledge, audio recordings
and documents of previous scholars. Researchers then proceed to review the data obtained from
these many sources; throughout the process categories (primary) and additional categories are
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generated, and the creation of theories are introduced. Creswell (2007) states that assumptions,
worldviews, bias about the study and the participant pool should be established initially.
Creswell (2008) noted that qualitative researchers play the primary role as a tool in data
collection they embark personal values, biases and assumptions prior to the study. In this
research project, data was recorded from open-ended and close-ended interviews and
questionnaires with participants. This form of recording was provided via electronic digital
recording and note taking. I developed and designed the questionnaire/interview questions to
address the following research questions:
RQ1: How does a reimportation of prescription drug policy contribute to patients’ drug
adherence?
RQ2: What perceptions do patients have about reimportation drugs as related to
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chronic disease?
RQ3: What are the perceptions of key providers (physicians, physician assistants & nurse
practitioners) regarding the impact of reimportation drug laws on patient medication
adherents?
Pilot Study
A feasibility study (pilot study) was performed to determine the appropriateness of the
interview questions in order to yield a refinement component for better understanding and foster
responses that are necessary to answer the research questions. This study took place one day
prior to the actual research start date. The participants in this study yielded data that was not
utilized in the data analysis process. Conducting this feasibility study does not necessarily
guarantee success within this exploration, but could increase the likelihood of success. It is the
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desire of this feasibility study to fulfill a series of important functions that can yield valuable
insight for the primary exploration.
Bias Interpretations
Bias in qualitative research is a problematic concept, because qualitative researchers are
part of the process, and researchers vary in style and approach. The human element has been
stated to be the greatest weakness and the greatest strength of a qualitative method. Qualitative
research mandates explicit acknowledgement of bias, in contrast quantitative attempts to
eliminate bias completely. This research has bias components as well and must be declared. This
declaration is noted due to the confinement of all the fieldwork to one geographic location,
suggesting that other major markets are not represented. The uniqueness of this study requires a
sampling population of one locale (the state of Maine). This state is the only locale that can
provide the participant pool needed to execute said study because of new state policies for
reimportation. All participants were pooled from this region.
The research also notes bias within the educational and socioeconomic realm. The study
does not make any assertions of patients’ level of education on reimportation, pharmaceutical
drugs, and non-adherence levels. Thus, higher educated participants with knowledge of
reimportation, the pharmaceutical industry, and patients’ non-adherence could be excluded from
the study. Also, since a major component of the research is related to cost-related issues, one can
assume that socioeconomic factors play a significant role of the participants. Therefore, the more
affluent population may not be represented adequately in this study; income levels of these
participants are not a delimitation factor to this research.
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Ethical Considerations
The research project has conformed to all mandated requirements of Walden University
and Walden Institutional Review Board (IRB). I (as a researcher) “respected the rights, values,
needs, and desires of the informants” (Creswell, 2008, p.198). Articulation of the identity of the
study, the role of the research, and risks (if any) was given to all informants. Informants were
informed that all data collected will be kept in confidence and that they would not be identified
by first or last name. The informants were informed that their responses will only be seen and
reviewed by the researcher.
Informants were briefed on the importance of their rights to refuse to participate and that
they are under no distress or pressure to participate. Articulation to participants (patients) stated
that a small monetary (gift card) was being offered for their participation efforts by the
researcher. No incentives were negotiated with any institution. It was articulated that
participating in this research is strictly volunteer. Written permission from informants to proceed
with the study was received and documented. For those who choose to participate, they were
told at any time they could exit the project and it was solely their right to do so without any
repercussions. For any individuals (on site) who volunteered and assist in any manner, it was
articulated that protecting the informant’s data is of priority in this research study and a sign
confidentiality agreement was required. For any follow-up concerns (i.e. validation, credibility)
informants were handed a participation identification number in such that their questionnaire and
interview responses will match the informant.
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Sample and Setting
Sampling (in general) is a complex topic. Determining the appropriate number of subject
is one complexing aspect of sampling. Creswell (2007) states that an adequate number range for
a qualitative method consists of 10-30 informants; cost and time are important factors when
considering sample size. The sample size in this research (20 participants) is needed to develop
a well-saturated theory and is suitable for smaller participant pools (Charmaz, 2006). The
theoretical saturation consist of qualitative data analysis that have continued sampling and
analyzing of data to the point that no new data is identified and other concepts in the theory are
well identified and developed (Morse, 2007). Concepts and linkages have formed a theory and
verification (member checking) have been performed. This inductive analytical approach
concludes that no aspects of the theory remain hypothetical. Morse (2007) goes on to state that
all conceptual boundaries are marked. Allied concepts have surfaced, documented, and
delineated. Theoretical saturation is the belief of theoretical sensitivity; this assumption of
theoretical sensitivity is that data analysis is driven by the data collected.
The research atmosphere and settings are important components as they set the tone of
the research. For example, this research conducted research interviews on location in the state of
Maine; the logic behind this was that (participants) would feel the research is for official
business and provides a sense of comfort.
Informants were selected based on their ability to contribute to this research while
seeking a threshold of saturation (Creswell, 2007). This research reached out to a sector within
the state of Maine that uses reimportation drugs and who are familiar with this policy. This
study attempted to use the various sectors of the city of Portland, Maine for patients and the
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entire state for providers. Healthcare providers were selected via social media and they provided
their inputs. Patients were selected based on their interest from a poster. Also, patients were
approached and solicited (fact-to-face) for their help to this research.
When utilizing these providers it was the desire to encompass certain characteristics of
the providers. Since the interview questions have been designed specifically for the providers
and patients, it was important to have a manageable working relationship with the patients (from
the view point of the providers). Although the providers make up 50% of the participant pool
they have access (and will give their perceptions) to several patients; thereby rendering valuable
information (indirectly) about patients’ plight. In order for them to share this information, they
should process the ability to listen well resulting in a nonjudgmental approach. Strong doctorpatient relationship was needed for the sake of trust, respect and partnerships are a desired trait
as well. These characteristic components can influence the analytical process.
Patients and providers were called upon via email, social media and telephone
conversations before traveling to various site locations in Maine. Once these individuals were
identified it was necessary to invite them to the research study. Providers responded 100% via
email and social media. I formulated an email containing the research information and attached a
consent form and questionnaire and sent out to providers who met the criteria. The identity of the
study along with their rights was also articulated. Those accepting this opportunity signed and
returned the consent forms. Charmaz (2006) suggested that the focus of the research is the
ultimate driver of the project design, and the size of sample population. It is suggested that a
smaller studies with modest claims can achieve saturation sooner verses a study that is focused
on the process that spans disciplines.
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Methodology
A qualitative research study using grounded theory as the design was selected for this
project due to (a) literature review yielded deficits in data for reimportation and the effects on
patients’ adherence, and (b) grounded theory affords researchers the opportunity to compile a
theory (Creswell, 2008). In contrast to quantitative who employ experimental/quasiexperimental design that often controls the outcome of the research while restricting the focus of
attention (Rudestam & Newton, 2001). Patton (2002) suggested that quantitative methods have
the possibility of not capturing the total dynamics of the responses from the participants or how
the project affects the participants. According to Buckley & Waring (2009), researchers benefit
from the qualitative approach because it allows nuances of languages and behaviors to be
detected that can contribute to a qualitative approach often select nonrandom sampling that
yields inferences from the research as it relates to the whole population (Creswell, 2008). This
research study benefited from the use of convenience sampling, making a qualitative approach
more appropriate. (Rudestam & Newton, 2001) stated that there is no national standard approach
within social sciences “although a common understanding that chosen methods of inquiry must
rest on rational justification” (p.23). Patton (2002) observed that qualitative methods (grounded
theory) often produce significant details about smaller number of participants therefore, I
rejected ethnographic method because it required a large culture group setting that requires
researchers interpretations.
Case study was not a proper fit due to the limited number of participant’s need to
describe their experiences at a specific time (Creswell, 2008) and because of the individual
responses desired. I looked at the perceptions of this population with efforts concentrated on
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several participants at various junctures thus the narrative approach was not selected due to the
writing experiences of a single individual and the creation of a narrative story line that described
those events. The various past experiences and different backgrounds that are sought in this
study requires an individuality approach; the interpretations of the phenomenological approach
would not be appropriate as “shared beliefs” (Creswell, 2008) of the participants is the focustherefore rejected.
Qualitative approach was designed and developed in 1967 by researchers B. Glaser and
A. Strauss (sociologist) who beliefs consist that theories should be “grounded” and have a
genesis in the field. This method required a theory of interactions, and actions based on data
collected from the participants (Creswell, 2007). They also stated a revision to constructivist
grounded theory in which individuals construct both the phenomenon and the research process
through actions. More recent theorist advocated constructivist grounded theory thereby
introducing another perspective onto grounded theory procedures. Patton (2002) noted that a
constructivist looks at how variables are grounded, given meaning and how it plays out in
participant lives. Constructivist grounded theory gained support with its introduction by K.
Charmaz in (2006); yet other viewpoints were supported by A. Clark (2005). She (Clark) relied
on postmodern perspectives such as the political nature of research and the interpretation
(Creswell, 2007).
Grounded theory has several defining features that may be incorporated into a research
project; the researcher must focus on processes that have guided steps overtime thus, grounded
theory has movement. Researchers also seek (in the end) to conclude with a theory that may
come in many forms. But, in simple terms it (theory) defines the understanding of the data that
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was collected. Memoing is integrated as it allows researchers to write down ideas as the data is
collected and analyzed; this form of data collection is often in the form of interviewing,
questionnaires, focus groups and recorded memos (Patton, 2002). Lastly, data analysis is
performed to developed categories that aid the theory process while detailing additional
categories in which incorporates inductive style approach (Creswell, 2007). Using inductive
approach for analysis (a) processes raw textual data into a succinct summary format; (b)
develops clear and concise conceptual links between the evaluation and the summation drawn
that is concluded from the raw data; (c) develops a structure of the underlying framework of
experiences (Thomas, 2006).
Research Design
According to Denzin and Lincoln (1994), a qualitative study needs the interpretation of a
phenomenon within their natural habitats in order to make sense of the meanings informants
bring to the research. Qualitative research involves memoing, collecting information, sorting,
note taking, and data collection and coding about personal experiences of the informants; this is
acquired by interviews, interactions, historical, and visual text which are pivotal moments that
have a meaningful component in people’s lives.
Patton (2002) defined qualitative research as making an attempt to comprehend various
interactions in a situation. While purpose of comprehending is not to predict what may or may
not occur, yet rather to make every attempt to comprehend in depth the components of a situation
and the meaning that participants contribute during that moment. Qualitative research is the most
flexible techniques, it uses a variety of methods and structures that are accepted throughout the
research arena; from individual case study to very in depth interviews, these types of studies
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demand carefully constructed and planned designs. No standard structures have been adopted;
interviews, case studies, and survey designs are the most often used methods.
According to Rudestam & Newton (2001), qualitative design has 10 considerations that
researchers should realize; (a) the focus of the inquiry, (b) determine the worldview (paradigm)
to focus, (c) determine the fit of paradigm to the substantive theory, (d) one must decide on
where and from all data will be collected, (e) is there a need for additional phases of the inquiry,
(f) what instrument(s) will be used, (g) data collection and recording codes, (h) data analysis
process, (i) planning the logistics, and finally (j) plan for the validity process.
Several advantages are seen with qualitative techniques. Qualitative is quite useful when
subjects are too complex, and no simple yes or no hypothesis can be discerned. They
(qualitative) designs are easier to plan and execute. Many feel they are useful when financial
decisions have to be considered. Within a broader view qualitative designs often succeed in
generating useful information in contrast to quantitative; it (quantitative) can generate an
unproved hypothesis resulting in valuable time and resources being wasted (Shuttleworth, 2008).
There exist smaller sample groups with qualitative because it is not necessary to rely upon
sample sizes with qualitative.
Qualitative is not perfect; researchers must realize at very early stages that a lot of careful
thought planning is required (Shuttleworth, 2008). One disadvantage of qualitative is that data
cannot be statically (mathematically) analyzed in the same comprehensive manner as
quantitative; thereby only a general pattern is seen. Qualitative is design for various
interpretations due to the open, opinion and judgmental components and duplications are more
difficult due to the uniqueness of the design.
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Data Collection
All informants were coded with a participation identification number. Demographic
profile obtained consisted of: age, race, gender, smoking status, and chronic diseases. All
information from patients was collected at the study site in Maine with the exception of one
patient. The identity of the study was articulated, and the rights of the patients and providers
were given. For example, participation in the research is strictly voluntary and early withdrawal
is an option to the participants. All questions at this juncture were addressed. Moving forward,
individual interviews were performed. I utilized random sampling; this method increased the
credibility of this study. I located healthcare providers in the state of Maine that met the criteria
of the research. Providers were located via “Linkedin.com” a profession social media website.
The site allowed for identification of occupation, location, and other pertinent information that
was needed for selection. Upon reaching out to these professions and befriending them, I was
able to send them (directly via their personal email address) a detailed email explaining the
research. I also, attached the consent form and the questionnaire to the email. This method
allowed for the research to reach various healthcare professionals throughout the entire state of
Maine thus, a better representation of healthcare professions were obtained. Those who elected
to participate signed and returned the consent form and questionnaire.
The individual interviews for patients were selected instead of a case study (group)
because I wanted individuality. For example, I did not desire a response from PT3 to be based on
what he or she heard from PT7. Interviews consisted of open and close-ended questions
developed by the researcher; as suggested by Creswell (2008) a central question and subquestions was established. I initially engaged in dialog (ice breakers) in order to get the patients
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comfortable with me in their environment. I welcomed all questions related to the research and
my credentials. Engagement was be brief not to intrude on normal behavior patterns which could
cause a decrease in honesty (Creswell, 2007).
According to Birks, Chapman, & Francis (2008) memoing allows researcher to make
conceptual leaps of the raw data to those abstractions that gives explanation of the research
within the context that is examined; therefore memoing is applicable to this research project.
Electronic recordings of each interview was performed this aided the transcribing process. This
research project benefited from face to face (FtF) interviews for several reasons. According to
Opdenakker (2006) the interviewer and interviewee can directly have a reaction to what the other
does or says. One advantage of this synchronous communication is that answers are more
spontaneous from the interviewee. FtF can also aid this research due to social cues that are given
off by the interviewee. This method yields the interviewer additional information that can be
added to the study (Opdenakker, 2006). A combination of questions being read aloud and
informant’s responses will comprise the interview process.
Upon completion of the interview process, analyzing and transcribing commenced. This
process was performed manually in order to formulate codes, categories, themes, and subthemes.
Issues of Trustworthiness
Validity of this project will proceed with member checking by sharing the transcripts
with the informants. Goldblatt, Karnieli-Miller & Neumann (2011) noted that sharing research
findings from a qualitative method with participants, member-checking is perceived as a process
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formulated to increase research credibility and informant’s involvement. Throughout this process
and post interview, informants were given the opportunity to clarify any inaccurate information.
Data Analysis
Data from this research was coded manually and allowed the data to be converted into
themes (Creswell, 2007). The research consisted of interview questions consisting of close-ended
and open-ended format. Close-ended question consisted of age, gender, race, chronic disease
status. These questions contributed to the demographic profile of informants. Also, close-ended
questions within the interview questionnaire were formulated. These questions gave substantial
support to the overall research project, whilst supporting the research questions. Open-ended
questions allowed informants to explore and elaborate on their experiences pre-policy era and
post policy era, in the hopes they will convey true personal perceptions, experiences and
opinions. According to Throne (2000) data allows qualitative study to stand out with a category
of principles, assumptions, values concerning truth, and real life; in contrast, quantitative
research that uses the scientific methods to understand reality.
Data retrieved from this research project involved voice responses, informant’s reactions,
tonations (voice projections) and developed ques to identify and capture non-verbal reactions.
All interviews were held individuality. This design allowed the researcher to capture true
responses from the informant and decrease the “copy cat” response heard from other informants
(often) seen in group or case settings. Retrieved data was safeguarded according to Walden
University (IRB) guidelines. Information was (and is) stored on my personal computer, personal
cloud (virtual) account (which is password protected) and is safeguarded for future use for a
number of years that is applicable to Walden University (IRB) policies.
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Creswell (2007) suggested that field notes, interviews be situated in some type of order
for the purpose of analyzing. The purpose for this process is to develop core variables to aid the
relationship amongst codes and concepts, generate themes and subthemes that will be used to
generate a hypothesis. Coding was in three stages; open coding, axial coding and selective
coding. Each coding has specific features; categories are formed with open coding, assembly of
data in new ways is seen with axial coding, and linking the categories is seen for selective
(Creswell, 2007). Persistence, an innovative data-gathering approach, and inquiring mind, can
navigate a researcher into undiscovered worlds and provide rich data. The research made every
attempt to do this. I validated this research with member checking via repeating informant’s
statements back to them and allowing for any further corrections and clarifications in order to
verify the accuracy. To further validate, I used opposing views and contrasting viewpoints to the
themes that manifested.
Several interview questions have been developed and designed to address the three research
questions:
RQ1: Does a reimportation prescription drug policy contribute to patient drug
adherence?
RQ2: What perceptions do patients have about reimportation drugs as related to a
chronic disease (diabetes)?
RQ3: What are the perceptions of key providers (physicians, physician assistants & nurse
practitioners) regarding the impact of reimportation drug laws on patient medication
adherents?
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Two sets of questions were developed and designed in response to the research questions.
The first set is designed for the patients (informants) referred to as “Informant Questions” (I.Q.).
The next set is designed for the providers (physicians, nurse practitioners, and physician’s
assistants) referred to as “Providers Questions” (Pro-Q): see appendix.

The following (I.Q.) were used for research question-1 (RQ1); 1, 2, 3, 4, 5 (see
Appendix I).
The following (I.Q.) were used for research question-2 (RQ2); 6, 7, 8, 9, 10 (see
Appendix I).
The following (I.Q.) were used for research question-3 (RQ3); N/A (see Appendix I).
The following (PR-Q) were used for research question-1 (RQ1); N/A(see Appendix
P).
The following (PR-Q) were used for research question-2 (RQ2); N/A (see Appendix
P).
The following (PR-Q) were used for research question-3 (RQ3); 1, 2, 3, 4, 5 (see
Appendix P).
At the conclusion of this research process, I disclosed data analysis to all appropriate
parties and deliver hard copies including a copy to Walden University for publication into
ProQuest Dissertations or any other forum within the university.
Summary
This chapter briefly discussed and outlined the design (grounded theory) and the
methodology (qualitative) use for this research project. This approach and design method was
chosen because of deficiencies in the literature review material and because of the flexibility it
provides to informants for their opinions and feelings. Data collection was performed via
questionnaires, and interviews. All questions posed to the participants consisted of open and
close-ended questions; validation for accuracy was performed by member checking.
Chapter 4 will consist of the research findings, the process in which these findings were acquired
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and to analyze data that was discovered from the perspective of the informants in relationship to
their questionnaires and interview questions.
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Chapter 4: Results
Introduction
The purpose of this research was to investigate one component of patients’ nonadherence of prescription drugs cost- related non-adherence (CRA) and research if reimportation
of said drugs will have an effect on prescription drug adherence among the American population
who have a chronic disease. Two theories were used to navigate this study; a grounded theory
approach and Kurt Lewin’s organizational change theory. Three research questions were
devised from the theories:
RQ1: How does a reimportation prescription drug policy contribute to patients’ drug
adherence?
RQ2: What perceptions do patients have about reimportation drugs as related to a
chronic disease?
RQ3: What are the perceptions of key providers (physicians, nurse practitioners,
physician assistants) regarding the impact of reimportation drug laws on patients’
medication adherence?
To address these questions, 10 health care providers, and 10 patients were invited to
participate in the research. Health care providers who prescribe drugs in the state of Maine
consist of physicians, nurse practitioners and physician assistants; these 3 professions made up
the health care providers for this research. Patients consisted of individuals who have a chronic
disease that warrant refill of prescribing medications. Participants (patients) in the study were
diagnosed with several diseases such as diabetes, cancer, thyroid disease, hypertension, high
cholesterol and attention deficit disorder. They are currently taking medication for their
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conditions. In this chapter, the procedures utilized to ensure quality of the data will be discussed.
The population sample of study and methods used to analyze the data will also be discussed. In
chapter five, the research findings will be summarized.
Demographics
Upon receiving institutional review board approval from Walden University (Walden
University Institutional Review Board (IRB) approval number # 04-22-15-0289886; I contacted
several physicians, nurse practitioners, and physician’s assistants in the state of Maine. I also
reached out to patients via the public forums (social media-Linkedin.com) and from face-to-face
encounters upon arrival in Portland, Maine.
All participants were of adult age and met the criteria for the research that included:
diagnosed with a chronic disease, monthly medication use, a citizen of the state of Maine, and
knowledge of acquiring drugs from non-United States markets. The research yielded a majority
of Caucasian ethnicity but also included other ethnicities; a right mixture of males and females
were also involved.
Protection of Participants
As the researcher, I approached this exploration with the responsibility of protecting the
rights of all participants. This research had a focus to abide by the Health Insurance Portability
and Accountability Act (HIPAA) thereby, maintaining complete confidentiality of all data that
was collected. The names of all participants were not disclosed. The only identifiers utilized
were the conversion of names to patient and provider numbers (for example: PT1, PT2, PT 3…
and PR1, PR2, PR3-for providers).
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This research consisted of two sets of population sampling (patients and health care
providers). Several challenges awaited this process (in relation) to recruitment of candidates
from a great distance. I had no previous contact information on participants therefore, I had to
develop methods of communication and be creative in locating this specific population sample. I
decided to recruit providers first because of the strenuous work schedule I needed ample time to
reach them and to acquire their participation; I turned to social media in this effort.
I crafted a brief, detailed statement explaining the research and attached the consent form
and questionnaire to an email. This email was sent to several health care professionals in the
entire state of Maine. I befriended several individuals on social media website“LinkedIn.com”.
The social media site provided detail information of individuals that allowed for selections that
met the research criteria. For example one is able to see occupation, location, email address, and
other pertinent details that allow for selection. After their acceptance, I then sent the email
containing consent form and questionnaire. This method of recruitment allowed for multiple
providers from various regions of Maine to participate, thereby lending an accurate
representation of the health care population within this state. All patients’ data collection was
performed face-to-face in Portland, Maine. One exception was PT1 who submitted her answers
via email. All informants participating in this research agreed to the terms of the research by
signing the consent form and returning it with a completed questionnaire. Data collection from
participants (both patients and providers) was in the form of email submission, phone interview,
and face-to-face interaction.
Researcher as Instrument
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Researchers in qualitative methodology research are the primary instrument of the study
(Hatch, 2002). To maintain complete neutrality and increase credibility of the study, I scrutinize
my attitude and biases initially prior to the study. I also realized that different people have
different perspectives, and I must adapt to the participant on an individual basis. This adjustment
was needed to maintain consistency within the questioning and follow up process (member
checking). I anticipated various responses, gestures and behaviors and accepted answers as they
were (with further clarification when needed). I expected to succeed in collecting the data within
a particular timeline. And found that the citizens in Maine that I encountered (generally
speaking) were very welcoming and eager to help in the name of research.
Data Collection
The research study consisted of 20 participants n=10 (patients), n=10 (providers).
Patients answered a 10 question interview/questionnaire survey and providers answered a 5
question interview/questionnaire over a 12-week period. Data collection took place from April
23, 2015, to June 21, 2015. Providers’ data collection commenced initially because of the
various time constraints health care professionals have. I wanted to allow additional time for
them (if needed) and be flexible to their schedule. Thus, sending the questionnaire via email was
the most appropriate way that allowed for them to answer at their convenience while agreeing to
a deadline. Extended time was given to obtain the 10 participants that were needed. Patients’
answers were obtained in Portland, Maine after articulation of the research and receiving signed
consent agreements from all participants. Patients’ interview took approximately 10-12 minutes
to complete, and additional time for follow-up questioning was needed to clarify answers and to
perform member checking.
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Interviews/Questionnaires
I developed 15 interview questions to address and answer three research questions. Ten
questions focused on patients’ perceptions, and the remaining five were for the perceptions of the
health care providers. Interview questions PT1, PT2, PT3, PT4, and PT5 were formulated to
answer Research Question 1: How does a reimportation prescription drug policy contribute to
patients’ drug adherence? I utilized interview questions PT6, PT7, PT8, PT9, and PT10 to
answer Research Question 2: What perceptions do patients have about reimportation drugs as
related to a chronic disease? These two research questions had a focus on patients’ perceptions. I
used interview questions PR1, PR2, PR3, PR4, and PR5 to address Research question 3: What
are the perceptions of key providers (physicians, nurse practitioners, and physician’s assistants)
regarding the impact of re- importation drug laws on patients’ medication adherence?
Transcription of data was completed after leaving the Portland, Maine research site. All
questions were developed as open-ended questions to foster more detailed answers from the
participants.
Providers’ questions being sent out via e-mail (electronic mail) address afforded the
opportunity for participants to take their time and address the questions without any external
factors. Thereby, they were able to perform a self-member checking before submitting their
responses to me. But upon receiving answers, I thanked the participants for their help. During
this line of communication, I asked if any information should be added or changed (member
checking). One exception ensued with PT1 who submitted her answers via email. PT1 was
afforded the same self-member checking as the providers and a follow-up email to her was sent
for member checking as well. Upon receiving the answer, I found no ambiguity; all the answers
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were clear and well understood. Although questions were open- ended and remained unchanged
post-pilot study some responses were short and required further probing to understand further
what the participant was attempting to say. The interview schedules for both providers and
patients are listed in Tables 1 and 2. Provider’s schedules were developed based on the receipt of
the answers via e-mail. Assignment of identifiers numbers were randomly given (immediately)
upon receipt of answers. Patients’ identifiers were given immediately following their interview;
PT1 was the only patient to respond via e-mail on May 22, 2015; all other patient surveys were
performed face-to-face.
Table 1- Schedule of Interviews/Questionnaires Surveys (Providers)
Date

Providers (PR)

5/1/2015

7

5/2/2015

10

5/2/2015

8

5/3/2015

3

5/4/2015

2

5/7/2015

6

5/7/2015

1

5/10/2015

9

5/11/2015

4, 5

---------------------------------------------------------------------------------------------------------------------
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Table 2 -Schedule of Interviews/Questionnaires Surveys (Patients)
Date

Patients (PT)

5/22/2015

1

6/17/2015

2

6/17/2015

3

6/17/2015

4

6/17/2015

5

6/17/2015

6

6/17/2015

7

6/17/2015

8

6/17/2015

9

6/17/2015

10

(Patients 2-10 interviews commenced throughout the entire day on 6/17/2015)

Data Analysis
This research performed an inductive data analysis of collected raw data that consisted of
transcription, coding the data, placing data into categories and reducing data to themes and subthemes. The purpose of this is to condense textual data, establish clear links among research
objectives and to summarize findings (Thomas, 2006). I utilized constant comparisons, sought
concepts, themes and experiences of the raw data using open and selective coding (Charmaz,
1990). I manually coded the data to develop themes by extensive comparison of the data. I
looked for patterns, similarities, and contrasting answers that would address the three research
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questions. Selective coding was used to establish a core variable. Codes were then transferred to
themes and sub-themes that I found to be more salient.
Axial coding aided this process and allowed for an open coding category to generate a
“core phenomenon” (Creswell, 2007, p. 66). And it allowed for the data to create categories
around this phenomenon (Creswell, 2007). I addressed and answered three research questions in
this exploration developing semi-structured open-ended questionnaires/interviews of
participants; these relationships of the results that emerged from data collected will be discussed
in subsections that will follow.
Interviews/Questionnaires
Ten providers responded to five questions, and 10 patients responded to 10 questions.
The collection of data consisted of electronic mail responses, phone interviews and face-to-face
interviewing. I coded all data with open- ended coding by segmenting all interview questions
that addressed and answered each corresponding research question. Table 3 indicates succinct
answers to the interview questions and shows the corresponding research questions for patients;
Table 4 displays the answers and corresponding research questions for the providers.
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Research Question 1
Interview Questions PT1, PT2, PT3, PT4, and PT5 answered Research Question 1: Does
reimportation prescription drug policies contribute to patients’ drug adherence? Overall, the
answers to questions IQ1, IQ2, IQ 3, IQ4, and IQ5 demonstrated a positive perception for
reimportation policies and a positive contribution to medication adherence. In response to IQ1
(40%) of the 10 participants felt drugs from the Canadian market are safe; while (30%) have
some reservation about drugs from non-United States markets. PT7 stated “I am concerned about
the ingredients in the medication” and PT10 had concerns about expired drugs and counterfeit
drugs. PT3 stated: “United States drugs only” was her preference and PT5 had concerns of drug
abuse from these markets. When I further probed about his drug abuse statement he stated that
the “cheap cost” could cause the abuse.
IQ2: What concerns do you have if you are unable to take your medication? Seven (70%)
of the 10 participants are concerned about their current medical condition worsening when they
are unable to take their medication with 30% fearing death. PT1 was also concerned with being
placed in a nursing home. Only 10% of the patients are concerned on how to obtain and pay for
the medication. PT4 is concerned with side effects.
IQ3 answers demonstrated that 40% were experiencing savings or expected to save
money with the reimportation policy in place. PT2, PT4, PT8 stated “no cost savings at this
time” because of current medication insurance that only utilizes the United States pharmacies.
The stated these insurance companies “pays all cost” or (as stated) by PT2 “I have a very low copay.” In response to IQ4, eight of the participants stated a positive response to “if cost were not a
factor”. PT1 stated: “would be a great thing.” PT2, PT6 and PT8 stated “would be able to take
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prescription.” “Would feel better” was the response from PT4; while PT9 responded “best
thing!” “Devastating if cost was a factor” responded PT10. Only PT3 stated there would be “no
impact”. PT5 responded: “this could be a double edge sword”, after follow-up questioning he
states it could be “good and bad”.
In response to IQ5: Please explain if cost has or has not affected your ability to follow
your drug regimen? Cost is affecting or has affected patients’ ability to obtain and take their
medication; 40% of the patients stated this. PT9 stated that cost has affected her because she
“lives pay check to pay check”. Insulin cost is unaffordable for PT5 she responded “I can’t
afford my insulin without the reimportation policy.” PT2 responded “that paying anything for
medication out of pocket is a concern.” Forty percent of other patients say cost is not a factor
because of current insurance from job or state. PT6 (a cancer patient) gets all her medications
from Canada and stated “cost is not a factor because of the Canadian market.” Past cost was an
issue for PT8 but not anymore because as he stated “it is not a problem now since I cross the
border.”
Research Question 2
Interview Questions (PT6, PT7, PT8, PT9, and PT10 answered Research Question 2:
What perceptions do patients have about reimportation drugs as related to a chronic disease?
IQ6 had a response of 50% that are favorable towards safety of Canadian pharmacies. PT1 stated
“safe because of Canada’s reputation”.” PT7 and PT8 responded with “possibly” and “not sure”
respectively. PT4 and PT10 stated “not safe” because of “incorrect chemical compounds” and
“no” because “I just don’t know the pharmacy.”
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IQ7 had a 50% positive perception of the reimportation policy and obtaining drugs from
Canada in comparison to the United States markets. The understanding of the reimportation
policy varies. All patients were aware of the ability to use the Canadian market. I interpreted the
Canadian market and the United States market to be on an uneven playing field. PT1, PT2, PT3,
PT5, and PT8 responded favorably. PT1 responded: reimportation that allows for Canadian
drugs are “safe and affordable” in comparison to the United States local markets. PT2 believes
“drugs are the same” as the United States drugs. Although it takes a little longer to receive, it is a
“good once I receive them” stated PT5. Twenty percent stated unfavorable answers; PT10
understanding of non-United States markets is that all drugs come from undeveloped nations and
that “Americans should stay away from them”. PT6 is a cancer patient who consumes a
$2000.00 drug every month (if purchased in the United States) for her cancer treatment. But she
gets her medication from Canada (every month) for only $30.00 co-pay. Thus, her
understanding is that “doctors and officials are not helping citizens, and those costs are
controlled by the government”.
In response to IQ8: patients’ preparation for future use of the policy and the Canadian
market indicated 40% will consider using the Canadian market to obtain medication; to allow for
adherence of their regimen. PT1 responded “will use Canada drugs.” PT4 and PT9 stated “would
consider cheaper market”. PT3, PT5, and PT8 indicated no preparation for long term use as it
relates to their medication. PT7 and PT10 preparation is to “use United States drugs only”. PT2
states she will continue ongoing consultation with her physician to see what is best for her.
IQ9 indicated (60%) of patients are not consulted by their health care providers on
affordable drugs and how these affordable can increase adherence. PT3, PT6, PT7, and PT9 were
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the only patients who stated they are consulted on affordable drugs. Generic drugs were the
affordable medication options given to PT3 and PT7 by providers. Consultation for using
reimportation drugs from non-United States markets were not mentioned by any provider. In
response to IQ10 concluded with nine patients 90% indicating that purchases from international
markets are not applicable in relationship to the total management of their current disease. After
follow-up questioning, the majority of answers demonstrated that there is no way to link
exclusively the international markets solely to disease management. Their drug purchases are
inter-mixed with drug purchases from the United States. One exception to this is PT6. Recall,
PT6 gets her $2000.00 medication from Canada for $30.00 co-pay thereby, management of her
disease is greatly increased and the reimportation policy has helped.
Research Question 3
Interview Questions (PR1, PR2, PR3, PR4, and PR5) addressed and answered Research
Question 3: What are the perceptions of key providers (physicians, nurse practitioners, and
physician assistants) regarding the impact of re- importation drug laws on patient medication
adherence? The overall answers for all interview questions from the providers demonstrated a
positive/good optional program. Providers responded (100%) favorable that the policy can
improve patients’ adherence. PR1 and PR5 responded “cheaper drugs, they will take” PR3
responded “the Canadian market helps to stay on meds.” “Much likely to stay on prescription”
stated PR4. Access to affordable drugs helps many of my patients” stated PR6. PR9
responded:”patients will stop taking medication if cannot afford”. “More likely to obtain if cost
is less as in Canada” stated PR10.
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IQ2 answers indicated that (100%) of the providers feel discussing medication adherence is
important at every visit. Words such as “always”, “each visit”, every visit” and “during regular
visits” were used. The majority of focus (70% of providers) stated that during consultation, the
focus was on taking the medication and if not taking, then why? PR2 states that education about
the medication was a main focus in consultation about adherence. Other answers were “dose
verification”, “safety”, and “side effects” were topics of conversations when speaking about
adherence.
IQ3 responses demonstrated a positive response from 80% of the providers stating that the
policy will have a positive effect on adherence levels. PR4 and PR9 were the only participants to
state that “it is too soon to tell” of any effects from the policy.
Providers stated words such as “ helpful”, “affordable”, “makes a big difference”, “will have
an effect” and “would provide a good option”, and “affordable drugs a big help”. PR1 stated
“that a policy is not going to change people mindset they will continue to cross the border here in
Maine for medication it was going on before the policy and will continue.”
Provider’s ability to monitor patients’ health solely based on where drugs are purchase is a
difficult task. Thereby, 80% of the providers stated that they don’t know of any direct link to
adherence of the policy at this time. Answers such as “can’t say” and “have not noticed any
major changes” were given. Provider’s response to IQ5 exhibited favorable perception to the
benefits of the reimportation policy. They (providers) stated “ cheaper”, “reputable”,
“reasonable cost”, “medication for less”, “helpful because of cost”, and “competitive “. PR7 was
the only provider to state “not sure yet.” IQ5 elicited some concerns from providers as they
stated “the legality and extra effort is needed” also “quality assurance and safety could be an
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issue” stated PR4, PR8 and PR9. PR2 stated that the “lack of effort to big Pharma to make meds
affordable is not there.”
Themes
Diagrams to demonstrate and organize the relationship of concepts, themes and
categories are important (Corbin & Strauss, 2008). Constructing theories though concepts can be
generated in many different ways; the relationships are based on the data obtain and is grounded
in the data (Corbin& Strauss, 2008). Therefore, I developed three diagrams to demonstrate the
relationship between dominant themes and subthemes that were influence from constant
comparing and analyzing the raw data. Figure-1 corresponds with themes related to the
providers; Figure-2 corresponds with themes related to patients’ responses and Figure-3 is
corresponding to common themes seen from both providers and patients.
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Providers’ Theme 1: Dominant Theme
Contribution to increase adherence level: Providers demonstrated overall that a
reimportation policy contributes now and can contribute in the future to adherence levels
positively. This theme emerged from IQ1, IQ3, and IQ5. In answer to IQ1, what asked: Describe
how this policy can improve patients’ adherence? Seven providers (70%) stated adherence will
increase because “patients are able to obtain and take medication” and “Canadian market helps”.
Other statements followed such as “cost is a factor, more likely to take them” and “will take
advantage of affordable drugs.” My interpretation is that affordability is the incentivized driving
force.
Providers’ Theme 2
Affordable drugs/cost effective: Providers indicated that cost is a factor and a major
cause why patient will seek these drugs and thus take them. This emergent theme comes from
IQ1, IQ5. Providers responded to IQ1 with “cheaper”, “less expensive”; IQ5 answers elicited
“lower cost” and “reasonable cost”.
Providers’ Theme 3
Reimportation Overall effect: IQ3 and IQ5 demonstrated an overall positive response.
IQ3 asked how this policy affects patients’ adherence; five providers responded favorably stating
“more likely to adhere” and “a good option.” IQ5 demonstrated favorable answers; when asking
providers to describe the pros and cons of this policy long term, three providers stated “helpful
because of cost” and “safe”; other answers were “competitive because of lower cost”.
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Providers’ Theme 4
Drug Safety/Quality Assurance: Forty percent of the providers demonstrated a positive
safety response as emerging from IQ5. Responses included “reputable” and “no concern for
safety coming from Canada.”
Providers’ Theme 5
Consultation/Education: This theme emerged from IQ2. All providers stated that
consultation and education of drugs were very important; and the importance of adherence is
discussed at “every visit”, “each visit” and “always” stated providers.
Providers’ Theme 6
Unaware of policy: This theme emerged from IQ4 as two providers were unaware of the
policy but have patients that cross the border to secure drugs. PR1 stated that “no policy matters,
they will still get meds with or without a policy from Canada.” These two providers’ answers
stood out because it indicates that 20% of the providers are unaware of a policy that can help
their patients. My interpretation is that increase communication and education are mandated.
Provider’s Theme 7
Positive effects on current condition: Providers indicated that IQ3 answers to current
conditions were helping with the use of the Canadian market. PR4 stated “yes and a few people
outside my area are getting meds from Canada.” PR3 responded “we need similar pricing here in
the United States”, makes a “big difference” stated PR2. Other favorable responses were “would
provide an option” and “patients are finding alternative therapies in Canadian pharmacies.”
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Patients’ Theme 1: Dominant Theme
Potential Adherence: Patients demonstrated a positive perception for reimportation of
current and future adherence. This theme emerges from IQ1, IQ3, IQ4, IQ6, and IQ8. In
response to IQ1 and IQ6: What concerns (if any) do you have or have had about medication drug
purchases from non-United States markets: forty percent of participants stated no concerns and
feel drugs are safe and 20% stated “possibly”. Four patients say they are saving money and
expect to save money (in response to IQ3). In response to IQ4, 90% stated adherence would
increase if cost were not a factor. IQ8 answers yielded a 30% positive response for future use of
Canadian markets, 30% stated they have no idea about what to do for future preparations. And
20% responded they will stay exclusively with United States pharmacies.
Patients’ Theme 2
Consultation/Education: This theme stemmed from IQ6, IQ7, and IQ9.This theme
emerged from answers and follow-up questioning from participants. My follow-up questioning
leads me to intrepid that patients do not completely understand reimportation protocol. These
drugs are manufactured in the United States and shipped out to other nations and then returns to
the United States. In response to IQ6: Do you feel drugs are safe? Twenty percent stated “no”
and 20% stated “possibly” or “50/50 chance they are.” But 40% responded favorable to safe
drugs from Canadian pharmacies. IQ7 answers yielded several variances to the question of how
do you perceive the overseas drugs in relationship to local drugs? PT3 and PT4 responded
“none”, PT1and PT8 stated affordable and “cheaper”. Other answers included PT2 respond that
he understands “drugs are the same as United States” and 20% of patients (PT7 and PT10)
responded that they will use only United States drugs. I interpreted additional education on the
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topic could renderer increase favorable answers. In response to IQ9: Eighty percent of patients
stated that they are not given information to seek more affordable medication from their health
care provider. My interpretation is that additional education to providers is also needed for them
Patients’ Theme 3
Cost Effective: Several patients stated that cost is a driving force for taking their
medication now and the future. This theme emerged from IQ3, IQ5, IQ7, and IQ8. The answers
for IQ3 are you experiencing cost savings or expect to save money: demonstrated that 40% of
patients are saving or expect to save because of the reimportation policy. Six patients gave
various reasons why they are not saving on Canadian drugs mainly stating that current
employment insurance or Medicare is covering all prescription cost. Patients in IQ5
demonstrated that 40% of patients stated cost has a direct link in their ability to follow
medication regimen. Fifty percent of patients stated no direct effect of management of their
disease because of reimportation drugs; there is no exclusivity on Canadian market and drug
purchases for current disease consist of United States’ pharmacies as well. Thirty percent of
patients stated “affordability” and “less expensive” answers when contrasting the United States’
pharmacy markets. Other patients’ answers suggested “additional research is needed” and “only
United States medication” was preferred by one patient. In response to IQ8: Forty percent of
patients stated that cost will be a factor in the future for adherence to drug regimen, and they will
consider the Canadian market.
Patients’ Theme 4
Drugs are safe: This theme emerged from IQ1, and IQ6. In response to IQ1, What
concerns do you have about medication drugs purchased from non-United States markets? Four
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patients stated they had no concerns, and with one patient stated “drug abuse”; while another
patient is concerned with “counterfeit drugs” and “cutting corners.” IQ6 asked: do you feel drugs
are safe from these pharmacies (overseas) if so why and what concerns do you have (if any)?
Forty percent stated “yes” two other patients responded “possibly” and one patient stated “not
sure.”
Patients’ Theme 5
Reimportation policy helps to manage current condition: This theme emerged from IQ10
that asked: How has reimportation policy help you to manage your disease? Only one patient
(PT6, who exclusively gets her meds from Canada) responded positively on this question. One
other patient stated “this is a good option”. The remaining patients 80% stated that there is no
link to the policy and management of their current disease. Upon follow-up with these patients
the majority responded that there is no way to exclusively (directly) connect the policy and
Canadian drugs (to their management) when they also get medications from the United States.
Patients’ Theme 6
Current Condition Concerns: This theme emerged from IQ2 that asked what concerns
you have if you are unable to take your medication. All patients (100%) stated that their inability
to take medication is a big concern and will seek alternative therapies to get their medicine.
Three patients stated “death” as a concern, and seven patients are concerned with current
condition worsening.
Patients’ Theme 7
Future use of Canadian Market: This theme was created from IQ8. Four patients 40%
are prepared to use the Canadian as a primary and supplement market for their future needs; they
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stated cost as the reason. Three patients (30%) have no idea about their plans for future use and
two patients 20% will continue to stay with the United States markets only.
Discrepant Case
Researchers should make every effort to locate discrepant cases (Merriam, 2002). This
research study invited 20 participants (10 providers, and 10 patients). PT3 did not completely
align with answers from other participants. This participant’s initial answers were short and only
stated his “allegiance” to American products. Many of his answers were “United States only!”
for questions that did not warrant such answers. Further probing and questioning of this
participant yielded a minimum additional clarification and understanding (but not much).
Conclusion
The findings in this research emanated from responses to interview questions observed
for a 12-week period. Ten health care providers and 10 patients were invited to participate in this
research that explored the perceptions of providers and patients in relationship to medication
adherence levels and reimportation of prescription drugs. The answers from this three month
long study demonstrated that health care providers and patients in the state of Maine have a
positive perception of reimportation, and that said policy can contribute to increasing drug
adherence that is incentivized by affordability.
Although additional education and discussions are needed, participants’ answers reflected
a favorable perception on the subject. At this juncture the playing field is not even when
contrasting medication drugs from the international market and the United States markets. Media
attention, advertisements and further understanding of reimportation must become more
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equivalent for reimportation drugs, until then, it is my conjecture that favorable responses are not
maximized.
This chapter outlined the population that took part in this exploration, how participants
were protected, the role of the researcher, and the procedures utilized to ensure the quality of raw
data collected. Also detailed was how data was collected, and methods used to analyze the data.
Chapter five will summarize the finding of this study. I will discuss the relationship of the
findings to the theoretical framework, a make inference to conclusions, briefly discuss
implications for positive social change, and suggest recommendations for future research on this
topic.
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Chapter 5: Summary, Conclusion, and Recommendations
Introduction
The need for supplemental, affordable medication programs, and policies has been a
growing topic within the health care arena. Patients’ adherence levels of many chronic diseases
continue to plague the medical field with growing distinction, soaring monetary costs, and
illnesses. Health care officials for many years have debated the effectiveness and safety of
reimportation drugs. This study went into the field to see what patients and health care providers
have experienced; and to capture their thoughts, opinions, comments, experiences and listen to
their voices. Providers who prescribe these medications have a role and voice in this matter as
well. I wanted to see what these providers who are on the “front line” every day have to say
concerning adherence levels and reimportation drugs. They are helping to change the plight of
their patients through consultation and prescription drugs and any improvement to the health care
system can aid this process.
It is very important to identify the components that can aid patients in the development of
good, effective and solid policies. I expected only veracious answers from each participant and
did not form any opinion prior to engaging in the research. My total commitment was to allow
the results to yield a conclusion. Participants approached me and the study in a welcoming
manner. The people of Maine displayed a level of sincerity to this topic by responding positively
to me and the study. Interpretation of findings for the study, the conclusion, implication for
positive social change, and further recommendations for this study ensues within this chapter.
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Interpretation of Findings
I conducted the study in the state of Maine where citizens are allowed to purchase
prescription medication from non-United States pharmacies. In Maine, the reimportation market
is better known as the Canadian market. Although the reimportation policy allows for purchases
from United Kingdom, New Zealand, and Australia, Mainers (people from Maine) can relate to
only the Canadian market; this was a realization from the pilot study.
The design of the study was qualitative with a grounded theory approach. The purpose of
the study was to see if reimportation policies have an effect on patients’ adherence levels. Three
research questions were developed to 15 interview questions to gain insight of health care
provider’s and patients’ perceptions. The research questions were answered by analyzes of
participant’s answers to open-ended interview questions within a natural setting. Ten patients
and 10 providers responded to 10 questions and five questions, respectively. Data collection for
this study used member checking to add credibility to the research.
Limitations of the Study
Within every endeavor there exist shortcomings; within this study one limitation is the
fact that only one state has a reimportation law. Also, the majority of Maine’s population is
Caucasian descent. These factors limit the research as other ethnicities are not fully represented.
Although this research did have two minority patients participate, the overall make-up of the
sampling pool was voided of minorities.
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Interviews
Research Question 1: How does a reimportation prescription drug policy contribute to patients’
drug adherence?
Patients’ answers demonstrated a positive outcome to this question. In response to IQ4:
Can you describe the impact of your taking your medication (as prescribe) if cost were not a
factor? Patients stated that reimportation of drugs had contributed to obtaining medication and
taking them. The words used by the various participants included “much likely to stay on meds,”
Canadian market helps to stay on meds,” “if cheaper, able to take meds”, “affordable medication
a big help”; along with “helpful”, “will have an effect”, and “more likely to adhere.” PT5
responded to IQ5 that asked: please explain if cost has or has not affected your ability to follow
your drug regimen? His response was “yes otherwise I cannot afford my insulin.” The responses
to the interview questions demonstrated an overall positive perception to reimportation policies
and increases drug adherence. Many patients (40%) demonstrated no concerns about medication
coming from the Canadian market. Additionally (40%) of patients are very concern if they are
unable to take their medication and fear worsening of their current disease stating that affordable
medication can resolve this issue.
Research Question 2: What perceptions do patients have about reimportation drugs as related to
a chronic disease?
Another focus of the study was to explore the perceptions of patients about reimportation
policies and adherence levels. Participants (overall) demonstrated a clear perception of this topic
with favorable an answer. Patients’ answers consisted of “safe”, “affordable”, “drugs are the
same as the United States”. Patients indicated they would use the Canadian markets for future
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medication needs to remain adherence. A two patients indicated “not sure”, or “possibly” to IQ6
that asked: do you feel the drugs from these pharmacies (Canada) are safe? Based on answers
from IQ7, I interpret that they do not have a full understanding of the non- United States markets
pharmacies and the reimportation protocol. Other responses were “should stay away from it”,
from PT10 response and “better if local markets are used” as stated PT7. The answers to the
interview questions revealed that all patients experienced elevated levels of perception of
reimportation policies and drug adherence.
Research Question 3: What are the perceptions of key providers (physicians, nurse practitioners,
and physician assistants) regarding the impact of re- importation drug laws on patients’
medication adherence?
Providers in the state of Maine who prescribe medication were invited to participate in
this study. The answers indicated a positive, clear perception. Most of the providers indicated
that affordability is the incentive that would have patients adhering to their medication. For
example, words such as “cheaper,” cost is a factor,” and “less expensive” were used. IQ3 (PR):
How does this policy affect patients’ adherence levels? Seven out of 10 providers responded
positively to increase adherence to this policy. Providers responded well to safety and quality
assurance. PR5 responded that this policy “provides a good option.” Providers also agree that
future use of reimportation will enhance the adherence levels of their patients; words such as
“increase access to drugs for less, will increase adherence.” I encouraged all participants to speak
freely and to give their true feelings and experiences.
Responses to the three research questions confirm the theoretical framework on which
this study is based; Kurt Lewin’s organization change theory; unfreeze, change, and refreeze
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(Lewin, 1947). Although originally presented many years ago, it is still relevant today. The
theory’s first model (unfreeze); involves getting to a level of understanding that change is needed
and preparing to move away from status quo. The second model (change or transition); defines
the journey of movement that is made to changes. And finally refreeze; this is about getting to a
stability point once the changes have been made. The changes are understood and accepted by all
thereby, becomes the new norm (Lewin, 1947). The themes that resulted from participant’s
answers are outlined below:
Research Question 1: Does reimportation prescription drug policies contribute to patient
drug adherence?
Themes:
Patients felt adherences were contributed due to the affordability and the reimportation
policies.
Patients are experiencing cost savings.
Patients thought the impact of reimportation policy was a good thing.
Patients felt that not being able to take meds would worsen current state and would look
to non- United States markets to obtain.
Research Question 2: What perceptions do patients have about reimportation drugs as
related to a chronic disease?
Themes:
Patients felt cost had affected their ability to follow drug regimen.
Patients felt (overall) that drugs are safe from non-United States markets.
Patients have a good understanding of drugs from Canada in contrast to the United States.
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Patients stated that they would utilize the reimportation policy in the future.
Patients felt that consultation and education about affordable drugs were not given by
providers.
Patients stated that no direct impact on disease management on reimportation policy.
Research Question 3: What are the perceptions of key providers (physicians, nurse
practitioners, and physician assistants) regarding the impact of reimportation drug laws on
patients’ medication adherence?
Themes:
Providers stated drugs were affordable and this equates to adherence.
Providers stated adherence consultation is given each visit.
Providers can’t state any direct improvement due to policy.
Providers (overall) stated the safety of drugs was not a concern from Canada.
This research demonstrates that non-adherence and cost are problems (unfreezing).
Attention is needed to address the problem (change/transition), and new policies are needed to be
implemented (refreezing). This organization theory applies to the entire nation and new policies
(reimportation) should be considered on a national scale.
Recommendations for Further Study
This research utilized a convenience sampling of 20 participants all over the age of 18
years old. Similar and different studies should be conducted among a larger population. Studies
can look at specific chronic diseases or continue to focus on multiple chronic diseases as it
relates to adherence levels and reimportation of prescription drugs.
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I conducted the study over 12-weeks. I recommend that multiple longitudinal studies
could benefit this research and is recommended to understand further if longer studies (with a
significant amount of participants) would change the outcome of perceptions. Continued focus
studies of medication adherence levels should carry on along with specific studies of
reimportation concerns. Larger populations within and outside the state of Maine would benefit
future research on this topic. Several states are considering a new order of federalism (system of
government in which the same territory is controlled by two levels of government,
Cornelllaw.edu, 2014) and implementing their reimportation policies; the majorities of these
states are in the same region as Maine and have a close proximity to Canada. Once implemented,
studies in these states can possibly contribute to the subject matter.
I also recommend the continued education of reimportation policies protocol to the
citizens for whom it is intended for. Officials should continue to education health care officials to
this subject matter in both rural and non-rural areas; all health care providers should know that
such affordable markets are available for their patients.
Recommendations for Action
Political and health care officials who take on the authoritarian role within the health
care arena have the responsibility to implement policies that can benefit the general population.
These individual (officials) should consider the findings of this research when engaging new
policies related to this topic.
Because many individuals have a chronic need for affordable drugs program, planners
should be willing to break new ground and go against traditional methods and policies seen in
the past. Many of these methods are not sufficient and require additional support and funding.
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This study demonstrates that providers and patients see a benefit in reimportation policies and
indicates an increase in patients’ medication adherence with the aid of reimportation policies;
this could contribute to the change of plight for many Americans desperately seeking help. The
finding within this research should be considered.
The monetary value (savings) that this policy can have on a national scale is tremendous
thereby, the components of this exploration should be included when discussions are underway.
According to Brown and Bussell (2011), patients with chronic diseases, account for
approximately 50% of non-adherence. This level of adherence leads to increase morbidity and
death. And has an estimated $100 billion per year in costs; reimportation policies can reduce this
cost significantly.
Implications for Positive Social Change
According to a study by Medco Health Solution data in 2008, it indicated that 51% of
(Americans) children and adults were taking one or more prescribed medication drugs for a
chronic condition. This indicated an increase from 50% from 2004-2007 and 47 percent in 2001.
Medco examined prescribe medication records from 2001 to 2007 from a registry sample of 2.5
million customers (children to the elderly) in their database. Chronic medication consumption
concerned areas were seen in all demographic groups. Two-thirds of women 20 years and older;
one in four children and teenagers, 52% of adult men, and three out of four people 65 years or
older. Among senior citizens, 28 % of women and 22% of men take five or more prescribe drugs
regularly (Medco.com, Retrieve 2015).
This research can contribute to an entire nation. Prescription medications are the most
significant health care product to society. Everyone at some point will be affected by
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prescription drugs. And with increase life longevity many individuals will have a need to be
medicated at some point. Continued discussions of reimportation and adherence levels should be
taken very seriously. A dual process is being undertaken. First, patients are more likely to take
medication if cost is not a factor, and second, in doing so, a significant saving to patients and the
(health care) insurance industry ensues.
PT6 of this research is a good indication that this research is needed and that
reimportation policies are contributing to increasing adherence thus, saving lives. Recall, PT6
must have a $2000.00 cancer drug every month (that she only pays $30.00 in Canada). And
without the reimportation policy this much-needed drug would not be available. Likely, without
the medication it would contribute to a worse state, leading to death. This research and other
research on this topic are for all the PT6 in the nation who need a voice. The economic savings
to health care insurance companies along with savings to patients could yield additional funding
that can be repurposed to other health care issues such as research on various diseases.
Researcher’s Personal Reflections
I commenced my study in Public Health Policy because of several reasons. I often have
seen family members and friends suffer from not having the resources to purchase drugs
monthly. They often had to make the tough choice of paying for prescription medications or pay
other monthly bills. In medical school, I was so often saddened to see prescriptions written for
patients who later will return 6 weeks later for a follow-up appointment, only to indicate that the
prescription was never filled. Many times the patients would pull out the now faded, wrinkle
prescription and say “I can’t afford it doc”. We (as health care providers) often give out samples
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to aid this process but only so much can be done; other programs are needed to supplement the
efforts of prescription adherence.
This research demonstrates that reimportation legislation should be highly considered. I
feel that maximum benefits of a reimportation law will be seen with the extremely costly drugs.
The average patient may not see elite benefits with some existing drugs that are cheaper (as in
generic) and that are readily available anywhere in the United States. But that is not to say that a
reimportation law may not help the mass, I believe it will. So much research on this matter is
needed and the discussion should (in my opinion) remain in the forefront of health care officials
and lawmakers throughout the nation. Reimportation policies cannot be a “savior” for all drugs
and, for this reason, the research recognizes that reimportation does have some shortcomings.
Conclusion
The literature review of the research has disclosed inadequate research data for
reimportation policies and the impact on patients’ drug adherence. The literature review also
voids the voices of providers and patients in this regard. Rhetoric from politicians and
pharmaceutical companies display a proclivity for profits and not the voice of the people. There
exist gaps in the literature to address reimportation and any contributions to drug adherence in
the United States.
Although supplemental programs such as Medicare exists, and there is assistance from
pharmaceutical companies to help patients (such as sample medications), this does not suffice to
address adequately the problem. No one “fix” will aid patients in this endeavor; it will take the
continued efforts of many organizations and officials to passionately help resolve this issue.
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Reimportation can be one of many tools used to combat the problem of non-adherence, and
should seriously be considered on a national scale.
Events in recent months in the state of Maine (I feel) substantiated the need for this
research and further research on this topic is required. In February 2015, United States District
Judge Nancy Torresen struck down the Maine Pharmacy Act that allowed Maine residents to
purchase lower-cost prescription drugs from Canada, the United Kingdom, New Zealand, and
Australia via a broker. According to the judge’s 19-page ruling, the Food and Drug
Administration (FDA) has jurisdiction over the importation of all medications (Silverman, 2015).
Thus, at this juncture, of this study there exists no one state that has a reimportation law. But as
stated by one of the providers (PR1)of this study “patients will continue to get medication from
Canada with or without a policy.” Advocates for reimportation are in discussion to see if an
appeal is in order.
This study has reflected that providers and patients see reimportation as a tool that can
contribute to higher levels of medication adherence. This research is not suggesting that
reimportation policies completely replace existing programs that are in place. But, considerations
for reimportation to be reinstated in Maine and to be a top consideration for all other patients
(throughout this country) who voices have gone unheard. It is the duty of a nation to adhere to
policies that change the plight of suffering patients and be united as one.

95
References

Alliance for Health Reform, (2006).Covering Health Issues, Retrieved 2014 from
http://www.allhealth.org/documents
American College of Preventive Medicine (2014). Medication Adherence Time Tool: Improving
Health Outcomes. Retrieved 2014 from http: www.acpm.org.
Arfwedson, J. (2014). Re-Importation (parallel trade) in pharmaceuticals. WHO.org article.
Retrieved from http://who.org
Arias, D. (2004). Drug reimportation gains popularity with more states. The Nation’s Health.
Retrieved 2014 from Https://www.apha.org.
Basskin, L. (1998). How to identify the reasons for patient noncompliance with drug
therapy. Formulary (33).1.
Bhosle, M., & Balkrishnan, R., (2007). Drug Reimportation practices in the Unites States.
Retrieved 2014 from www.pubfacts.com/author/Rajesh Balkrishnan.
Birks, M., Chapman, Y. & Francis, K., (2008). Memoing in qualitative research
Probing data and processes. Journal of Research in Nursing 13 (1), 68-75.
Blue Cross-Blue Shield (BCBS) (2014). Medication non-adherence is associated with
increased medical health care cost. Digestive Diseases and Sciences
53, 4, 1020-1024.
Brown, M. & Bussell, J. (2011).Medication Adherence: Who Cares?
April 2011 Volume 86, Issue 4, 304-314.

96
Briesacher, B., Gurwitz, J., & Soumerai, S. (2007). Patients At-Risk for Cost-Related
Medication Nonadherence: A Review of the Literature. Clinical Review, Journal of
General Internal Medicine, June 2007, (22), 6, 864-871.
Buckley, C & Waring, M. (2009). The evolving nature of grounded theory: experiential
reflections on the potential of the method for analyzing children's attitudes
towards physical activity, International Journal of Social Research Methodology, 12(4),
317-334.
Burnes, B. (2004). Kurt Lewin and the Planned Approach to Change: A Re-appraisal. Journal of
Management Studies 41:6. Manchester School of Management.
Census.gov (2014). Division of Population Health Maine Center for Disease Control &
Prevention A division of the Maine Department of Health and Human Services.
Retrieved from http://www.Census.gov.
Charmaz, K. (2006). Constructing grounded theory: A practical guide through qualitative
analysis (2nd ed). London: Sage.
Cohen, R., Kirzinger, W., & Gindi, R. (2013). Strategies Used by Adults to Reduce Their
Prescription Drug Cost. Retrieved from CDC.gov.
Colgan, C, (2014). Maine Center for Business and Economic Research. Retrieved 2014.
Congress.gov, (Retrieved 2014). Https://beta.congress.gov/member/olympia-snowe/1085
Corbin, J., & Strauss, A. (2008). Basics of Qualitative Research: Techniques and Procedures
for Developing Grounded Theory (3rd Ed.). Thousand Oaks, CA: Sage.
Cornell Law, Retrieved, 2014. Http://www.law.cornell.edu/wex/federalism

97
Creswell, J. (2007). Qualitative Inquiry and Research Design; Choosing Among Five
Approaches. Sage Publication, 3rd Edition.
Creswell, J. (2009). Research Design: Qualitative, Quantitative and Mixed Methods
Approaches. Sage Publications, 3rd Edition.
Creswell, J. W. & Miller, D. L. 2000. Determining validity in qualitative inquiry. Theory into
Practice, 39, 3-11.Thousand Oaks, CA:, Sage
Dalmis, S., (2003). The Downside of Drug Reimportation. Chicago Tribune, Chicago, IL.
Dayen, D. (2009). FDA Letter Warns Of Safety Concerns With Re-Importation Of
Prescription Drugs.
DeAgostino, M. (2004). Pfizer exec: Canadian drug imports safe; Retiree group backs Kerna,
reimportation. South Bend Tribune, South Bend, IN.
Denzin & Y. S. Lincoln (1994). Handbook of Qualitative Research (pp.105-117). Thousand
Oaks, CA, Sage.
Dewar, H. (2002). Senate votes to Allow Drug Reimportation: U.S.-Made Pharmaceuticals
Could Be Shipped from Canada at Lower Cost. The Washington Post, Washington, D.C.
Emanuel, E., 2012. Where Are the Health Care Cost Savings? American Medical
Association. http.//www.ama.org.
FDA, PR News Wire, (2000). Eleven former FDA Commissions Warn of Dangers of Drug
Reimportation to American Patients, Reports PHrMA; Every Living Former FDA
Commissioner Since 1969 Says Reimportation is Dangerous.
Food and Drug Administration (FDA.gov) (Retrieved 2005). Drug Safety and Availability.
Http://fda.gov/drugs/drug safety/ucm179411.htm.

98
Frost & Sullivan, (2006). Patient Nonadherence tools for Combating Persistence and
Compliance Issues, www.frost.com

Gabriel, D., (2013). Inductive and deductive approaches to research.CRC Press Taylor & Francis
Group, Boca Raton, FL

Ganslandt, M. & Maskus, K. (2004). Parallel imports and the pricing of pharmaceutical
products: evidence from the European Union. Journal of Health Economics 23 (2004)
1035–1057.
Goldblatt, H., Karnieli-Miller O., and Neumann M. (2011). Sharing qualitative research
findings with participants: study experiences of methodological and ethical
dilemmas. Patient Education Counsel. Mar; 82(3):389-95. doi:
10.1016/j.pec.2010.12.016. E-pub 2011 Jan 22.
Gottlieb, H. (Retrieved 2014). Medication Nonadherence: Finding Solutions to a Costly
Medical Problem. Http://www.medscape.com/viewarticle/409940.

Hamburg, M. (2014). Office of the Commissioner-U.S. Food and Drug Administration.
Http://FDA.gov.

Hatch, J. (2002). Doing Qualitative Research in Education Settings. State University of New
York Press, Albany, NY.

Hess, G., (2000). Democrats accuse Pharma industry of gutting drug reimportation bill.
Chemical Market Reporter 258.16.
P. Michael Ho, P., Bryson, C., and Rumsfeld, J., (2009). Key Issues in Outcomes

99
Research Medication Adherence, its Importance in Cardiovascular Outcomes.
Jones, B., (2008). Medco Health Solution. Study shows more Americans taking prescription
drugs. Http://usatoday30.usatoday.com/news/health/2008-05-14- medicationnation_N.htm
Journalinquirer.com, (2013). Big Pharma profits at the expense of us all. Healthcare for
America Now.

http://www. journalinquirer.com/opinion/editorials/big Pharma-

profits.
Kaiser Health, (2006). Shalala Rejects Reimportation Plan. Retrieved from
http://khn.org/morning-breakout/dr00001973/
Kanavos, P., Vandoros, S. (2011). Determinants of branded prescription medicine prices in
OECD countries. Health Economics, Policy and Law 6.3.
Kanavos, P., Ferrario, A., Vandoros, S., Anderson, G., (2013). Higher US Branded Drug Prices
and spending Compared to other Countries May Stem Partly From Quick Uptake of New
Drugs. Health Affairs 32.4: 753-61.
Karmel, M. (2005). Clinical Update: Glaucoma Compliance, Adherence, Persistence. American
of Ophthalmology. http://www.aao.org
Kennedy, J., and Morgan, S., (2006). A cross-national study of prescription nonadherence
due to cost: Data from the joint Canada-United States survey of health. Clinical
Therapeutics 28.8 (Aug, 2006): 1217-24.
Klein, P., (2014). Pharmaceutical Industry haunted by support for government healthcare.
The Examiner, Washington, D.C.

100
Kurlander, J., Kerr, E., Krein, S., Heisler, M., & Piette, J., (2009). Cost-Related Nonadherence
to Medications Among Patients With Diabetes and Chronic Pain.
Lancaster New Era, (1999). The High Cost of Drugs is being Driven by Advertising. Lancaster,
PA.
Levitz, J. and Martin, T., (2013). Maine to allow Prescription-Drug imports. The Wall Street
Journal, New York, NY.
Lueck, S., (2002). Senators Input Drug-Reimportation Bill—Allowing Cheaper Medicines From
Canada Appears Easier Than Medicare Legislation. Wall Street Journal, Eastern Edition.
New York, NY.
Maine.gov (2014). Labor, Commerce, Research and Economic Development.
Http://www.Maine.gov/legislature.Retrieved from http://Maine.gov
Mayo Clin Proc., (2011). Apr; 86(4): 304–314. doi: 10.4065/mcp.2010.0575
Merriam, S., (2002). Qualitative Research in Practice: Examples for Discussion and Analysis 1st
Edition. Jossey-Bass, San Francisco, CA.
Morran, C., (2012). More Uninsured Americans Not Filling Prescriptions, Delaying Doctor’s
Visits, Skipping Medical Procedures. Consumerist. Http://consumerist.com.

Morse, J., Sep 15, (2007). Theoretical Saturation, Retrieved from Proquest database.

Moscovitch, B., (2001). AARP Back Drug Reimportation Bill, But Hurdles Persist. Inside
Washington’s FDA Week. 17.13.
Motheral, B & Fairman, K. (2001). Effect of three-tier prescription co-pay on
pharmaceutical and

other medical utilization. Med-Care: 39 (12) 1239-304.

101
Nordqvist C., (2001). Cost Causes Many Elderly Not to Adhere to Prescribed Medication
Regimen. Medical News Today. Http://www.medicalnewstoday.com.
Opdenakker, R., (2006). Advantages and Disadvantages of Four Interview Techniques in
Qualitative Research. Volume 7, No. 4, Art. 11 – September. Http://www.qualitativeresearch.net/index.php/fqs/article/view/175/391#g21.
NAPSRx, Retrieved, (2014).The National Association of Pharmaceutical Sales
Representatives, 2013. Sales Training Manual, Revised 13th Ed. National Institution of
Health.

Patton, M., (2002). Qualitative Research & Evaluation Methods. 3rd Edition, Thousand Oaks,
Ca.: Sage Publication.

Paul, D., Chandra, A., Lambrinos, F., (2006). Global Pharmaceutical costs: Evaluating the
American approach. Journal of Medical Marketing 6.1.
Pharaco Economics, (2003). European Healthcare Polices for Controlling Drug. Expenditure.
Vol. 21, issue 2, pp 89-103.
Pugh, T., (2004). Drug Reimportation looks like a cure for some political maladies. Knight
Ridder Tribune News Service, Washington, D.C.
Quon, B., Firszt, R., and Eisenberg, M. (2005). A Comparison of Brand-Name Drug . Prices
between Canadian-Based Internet Pharmacies and Major U.S. Drug Chain Pharmacies.
Annal of In Internal Medicine. American college of Physicians.

102
PR News Wire (2004). Freedom Works Co-Chairman Dick Armey Urges Private Sector
Solution for Prescription Drug Coverage in Light of Drug Reimportation Issue. Pr News
Wire, New York, NY.
Rudestam, E. & Newton, R. (2001). Surviving Your Dissertation, Comprehensive Guide to
Content and Process, 2nd Edition.
Ryan, T., (2004). Drug importation; CVS Corp. says prescription drug imports should be
legalized. Managed Care Weekly Digest. 31.
Safra, D., Neuman, P., Schoen, C., Kitchman, M., Wilson, I., Cooper, B., Li, A., Chang, H. &
Rogers, W., (2005). Prescription Drug Coverage and Seniors: Findings From a 2003
National Survey. Health Affairs, no. (2005). Doi:10.1377/hlthaff.w5.152.

Senate.gov, Retrieved, (2014). Affordable Drug Prescription.
Http://www.king.senate.gov/newsroom/press-releases/king- fights-to-protectaffordable-

prescription-drug-prices-through-reimportation.

Sha, R., Desai, S., Gajjar, B., & Shah, A., (2013). Factors responsible for noncompliance to drug
therapy in the elderly and the impact of patient education on improving compliance.
Springer International Publishing.
Shuttleworth , M., (2008). Qualitative Research Design, Explorable.com:
https://explorable.com/qualitative-research-design.
Swartz, J., (1995). Generics grow as patents run out: The High Cost of R& D is why makers
insist they must get a 20-year time span. Report on Health and Pharmaceutical, The
Globe and Mail. Toronto, Ont.

103
Thomas, A., (2007). Direct Marketing; An International Journal. Vol. 1 Iss: 1, pp. 6-16. Emerald
Group Publishing Limited.
Thomas, D., (2006). A general Inductive Approach for Analyzing Qualitative Evaluation Data;
University of Auckland, American Journal of Evaluation June 2006 vo. 27. 2 237-246.

Thorne, S., Retrieved, (2014). Data analysis in qualitative research. Evid Based Nurs 2000;
3:68-70 doi:10.1136/ebn.3.3.68
Toner, R., (2002). Maine at Front Line in Fight Over the High Cost of Drugs. New York Times,
Late Edition (East Coast). New York, NY 11 May, 2002.
Torrey, T., (2014). What Is a Health Insurer's Drug Formulary and Tier Pricing: Use the System
to Help Save You Money on the Cost of Prescription Drugs? (Http://www.theabpm.org).
The American Board of Preventive Medicine. Https://www.theabpm.org/aboutus.cfm
U.S. News Wire, (2004). New Study Finds Drugs Reimportation Policies Would Destroy Jobs;
Drastically Reduce the Number of New Drugs. Washington, D.C.
World Health Organization (WHO.org, (2003). How does poor adherence affect policy-makers
and health managers? Http://www.who.org.
World Health Organization (WHO.org.), (2003). Defining Adherence.
Http://who.org/adherence/documents.
Yates, T., (2013). Saving billions on prescription drugs. Gainesville Sun, Gainesville, FL.
Zall, M, (2001). The Pricing Puzzle. Vol. 4, No. 3, pp 36–38, 41, 42.
Http://pubs.acs.org/subscribe/archive/mdd/v04/i03/html/03zall.html.

104
Appendix A
Demographic Profile
In addition to interview questions, the following questions were asked of all participants in
relation to their demographic profiling:

Gender?
Race?
Age (range)?
Smoking?
Chronic Disease(s)?
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Appendix B
Flyer-Information Poster
Dear Prospective Research Participant,
I am Jeffrey Tubbs; a PhD candidate in Health Services at Walden University, conducting a research
study related to one component of patient non-adherence of prescription drugs and I am investigating if
reimportation of prescription drugs has an effect on patients’ drug adherence levels among participants
who have a chronic disease.
I am seeking participants to interview (face-to face) who speak English fluently and have a chronic
disease that requires monthly renewal prescription refills (on-going refills). Participants of the age of 18
years old and older are welcomed. Previously purchases of prescription medication from outside the
United States (such as Canada) are desired. The interview time span may last between 10-15 minutes.
At any time during the interview, the research participant may withdraw if he or she feels uncomfortable
with the content of the interview protocol.
This research is not affiliate with this medical institution; your participation or non-participation will not
have any effect on the treatment you receive or the relationship you have with staff members.
If you are interested please contact me via the below listed information. This research will make every
effort to conform to Health Insurance Portability and Accountability Act (HIPAA) in that all information
will be kept confidential and secure.

Sincerely,

Jeffrey Tubbs, MD, MBA, BSc.
PhD Health Services Candidate
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Appendix C
The following research questions (RQ1) corresponds to the following stated interview questions:
RQ1: How does a reimportation of prescription drug policy contribute to patients’ drug
adherence?
Interview Questions
1. What concerns (if any) do you have or have had about the overseas drugs?
2. What concerns do you have if you are unable to take your medication(s)?
3. Are you experiencing cost savings (from overseas purchases) of your drug medication
purchases (please explain why or why not)?
4. Can you describe the impact of you taking your medication (as prescribed) if cost was not a
factor?
5. Please explain if cost has or has not affected your ability to follow your drug regimen?
------------------------------------------------------------------------------------------------------------------The following research questions (RQ2) corresponds to the following-stated interview questions:
RQ2: What perceptions do patients have about reimportation drugs as related to a chronic
disease?
Interview Questions
6. Do you feel the drugs from these pharmacies (overseas) are safe if so, why and what
concerns do you currently have (if any)?
7. How do you perceive the overseas drugs in relationship to local drugs for long term health?
8. Chronic diseases are long term decision process; describe your preparation for this as it
relates to your medication drug choices?
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9. Are you given optional advice to seek more affordable medication from your physician, if so
what options were suggested?
10. How has the reimportation policy help you manage your disease?
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Appendix D
Providers Questions (PR-Q)
The following research question (RQ3) corresponds to the fore-stated interview questions:
RQ3: What are the perceptions of key providers (physicians, physician assistants & nurse
practitioners) regarding the impact of reimportation drug laws on patient medication
adherents?
Interview Questions
1. Describe how this policy (can) improve patients’ adherence?
2. How often do you consult patients about adherence of drug prescriptions?
3. How does this policy affect patient adherence levels or is it too soon to tell?
4. Describe any improvements with your patients’ adherence since this policy has been in
place?
5. Describe in your opinion the pros/cons of this policy long term?
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Appendix E
PhD Candidate: Jeffrey Tubbs, MD, MBA

Letter of Cooperation

(1.) Community Research Partner: (Research Site): _________________________________
_______________________________________________________________________
(2).Authorization from (Contact Information) Name:
_______________________________________________________________________

Date:
Researcher: Jeffrey Tubbs, MD, MBA (College of Health Sciences)
Based on my review of your research proposal, I give permission for you to conduct the study entitled
“Public Policy De Facto, New Order of Federalism: Re-importation of Prescription Drugs, a Major
Factor to Patient Drug Adherence” (3.)within_____________________. As part of this study, I
authorize you to conduct a full interview session with participant(s) and myself. Individuals’
participation will be voluntary and at their own discretion.
We understand that our organization’s responsibilities include: a small room that the partner will
provide. This (institution/individual) reserves the right to withdraw from the study at any time if our
circumstances change.
I confirm that I am authorized to approve research in this setting and that this plan complies with the
organization’s policies. Recruitment of participates (patients and physicians) are granted and they have
the right to deny any participation of the research process.
I understand that the data collected will remain entirely confidential and may not be provided to anyone
outside of the student’s supervising faculty/staff without permission from the Walden University IRB.
This research under-taking has been approved by Walden University Institutional Review Board (IRB)
approval number # 04-22-15-0289886 (expiration date: Apr. 21, 2016).
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Sincerely,
(4).Authorization Official (signature) __________________________________
----Hand signature---- or --------------The use of your email can be used to sign this document electronically--------

